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Abstract	  
The	  purpose	  of	  this	  study	  was	  to	  characterise	  biotransformation	  and	  immune	  responses	  in	  juvenile	  Atlantic	  cod	  (Gadus	  morhua)	  following	  exposure	  for	  2,	  8	  and	  16	  days	  to	  the	  water-­‐soluble	  fraction	  of	  North	  Sea	  crude	  oil	  in	  different	  concentrations.	  	  Biomarkers	  (ELISA,	  hepatic	  EROD	  activity	  and	  PAH	  metabolites	  in	  bile)	  were	  used	  to	  examine	  effects.	  The	  study	  also	  included	  oil-­‐related	  effects	  on	  DNA	  by	  assessing	  DNA	  damage	  with	  the	  comet	  assay.	  A	  third	  aspect	  of	  the	  study	  was	  quantifying	  immune	  responses	  related	  to	  oil	  exposure,	  which	  was	  done	  by	  measuring	  respiratory	  burst	  in	  leukocytes.	  A	  pathogen	  challenge	  in	  the	  form	  of	  LPS	  was	  injected	  after	  8	  days	  to	  assess	  if	  the	  immunocompetence	  changed	  as	  a	  result	  of	  oil	  exposure.	  	  The	  biomarkers	  of	  exposure	  were	  successful	  in	  linking	  oil	  treatments	  with	  elevated	  PAH	  metabolite	  levels,	  EROD	  activity	  and	  a	  change	  in	  CYP1A	  levels.	  There	  was	  no	  link	  between	  increased	  DNA	  damage	  and	  exposure	  to	  the	  WAF	  of	  oil.	  	  Furthermore,	  there	  were	  no	  treatment	  effects	  on	  respiratory	  burst.	  Injection	  of	  LPS	  did	  not	  appear	  to	  change	  immunocompetence.	  	  In	  total,	  the	  study	  provided	  good	  insight	  into	  effects	  of	  the	  WAF	  of	  crude	  oil	  on	  biotransformation	  pathways	  in	  cod	  as	  well	  as	  assessing	  immune	  responses,	  although	  the	  latter	  may	  need	  further	  studies	  to	  successfully	  contribute	  to	  risk	  assessment.	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1	  Introduction	  
1.1	  Concerns	  Regarding	  Oil	  in	  Marine	  Environments	  	  	  Both	  fisheries	  and	  offshore	  activities	  involving	  oil	  and	  gas	  are	  huge	  industries,	  especially	  in	  Norway.	  It	  is	  important	  to	  keep	  the	  conflicts	  between	  these	  to	  a	  minimum	  by	  monitoring	  and	  controlling	  the	  contaminant	  inputs	  and	  effects	  	  (Hylland	  et	  al.	  2008).	  The	  marine	  environments	  surrounding	  Norway	  have	  become	  an	  area	  of	  concern	  due	  to	  the	  high	  amount	  of	  petroleum-­‐related	  activities	  and	  the	  localization	  of	  large	  oil	  and	  gas	  reserves	  in	  the	  Arctic	  (Nahrgang	  et	  al.	  2010).	  Oil	  spills	  and	  extraction	  activities	  represent	  a	  threat	  to	  aquatic	  organisms,	  as	  spills	  to	  the	  marine	  environment	  expose	  them	  to	  the	  water-­‐soluble	  fraction	  of	  the	  oil	  (Nahrgang	  et	  al.	  2010).	  Marine	  organisms	  will	  often	  be	  exposed	  to	  low	  concentrations	  due	  to	  the	  dilution	  that	  occurs	  when	  the	  discharged	  products	  are	  mixed	  with	  the	  surrounding	  seawater	  (Hylland	  et	  al.	  2008)	  but	  nonetheless,	  it	  is	  important	  to	  continue	  monitoring	  and	  further	  develop	  biomarkers	  for	  PAHs	  to	  investigate	  effects	  in	  organisms	  in	  exposed	  areas	  (Nahrgang	  et	  al.	  2010).	  	  Further,	  when	  accidental	  oil	  spills	  occur,	  the	  concentration	  may	  be	  much	  higher	  than	  the	  background	  concentration	  present	  from	  continuous	  discharges	  from	  platforms.	  Discharges	  are	  usually	  in	  the	  form	  of	  produced	  water,	  which	  in	  addition	  to	  PAHs	  contain	  alkyphenols,	  metals	  and	  production	  chemicals	  (Hylland	  2006).	  	  	  
1.2	  Biomarkers	  and	  Immune	  Responses	  
	  Biomarkers	   to	   detect	   effects	   of	   PAHs	   have	   been	   increasingly	   used	   in	   studies	  during	   the	   last	   decades.	   Biomarkers	   generally	   function	   as	   a	   link	   between	   the	  contaminant	  and	  the	  biological	  effects	  of	   the	  contaminant;	   for	   this	  reason,	   they	  can	  be	  used	  to	  detect	  exposure	  and	  effects	  (Bucheli	  et	  al.	  1995).	  Phase	  I	  enzymes	  such	   as	   hepatic	   EROD	   activity	   and	   CYP1A	   levels,	   as	   well	   as	   biotransformation	  products	  such	  as	  PAH	  metabolite	  levels	  in	  bile,	  have	  been	  proven	  to	  be	  valuable	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and	   some	   of	   the	   most	   efficient	   fish	   biomarkers	   for	   environmental	   risk	  assessment	  (Van	  der	  Oost	  et	  al.	  2003).	  Studies	  using	  biomarkers	  may	  continue	  to	  contribute	  to	  gaining	  further	  knowledge	  about	  exposure	  effects	  and	  routes	  but	  as	  organisms	  in	  their	  natural	  environments	  are	  continuously	  exposed	  to	  pathogens	  and	  parasites,	  a	  good	   immune	  system	  and	   immunocompetence	   is	  vital,	  and	  has	  been	  directly	  linked	  with	  minimized	  fitness	  costs	  (Owens	  et	  al.	  1999,	  Graham	  et	  al.	  2010).	  More	  insight	  into	  immune	  responses	  and	  their	  possible	  correlations	  to	  other	   biomarkers	   will	   further	   contribute	   to	   risk	   assessment,	   especially	   in	  aquaculture.	  	  	  The	  immune	  system	  in	  fish	  and	  other	  vertebrates	  is	  divided	  into	  an	  innate	  and	  an	  adaptive	  part,	  both	  of	  which	  contain	  humoral,	  and	  cellular	  factors.	  The	  responses	  of	   the	   adaptive	   system	  are	   usually	   slower	   but	  more	   specific	   and	   can	   therefore	  make	  way	  for	  high	  variation	  of	  somatic	  antigen-­‐binding	  receptors	  from	  only	  few	  genes	   (Litman	   2010).	   In	   general	   cellular	   factors	   are	   immune	   cells	   such	   as	  macrophages,	  natural	  killer	  cells	  or	  granulocytes,	  while	  humoral	  factors	  may	  be	  the	   acute-­‐phase	   proteins	   of	   the	   complement	   system	   that	   can	   be	   activated	   to	  attack	  intruding	  microorganisms,	  cytokines	  and	  chemokines,	  lysozyme	  or	  others	  (Segner	   et	   al.	   2012).	   The	  humoral	   defence	   in	   fish	   contains	   certain	  non-­‐specific	  factors	   that,	   even	   though	   they	   are	   generally	   not	   fundamentally	   different	   from	  those	  in	  higher	  vertebrates	  such	  as	  mammals,	  do	  contain	  some	  different	  features	  (Yano	  1996).	  For	  instance,	  the	  optimal	  complement	  activity	  temperature	  in	  fish	  is	   different	   than	   that	   of	   mammals	   due	   to	   the	   temperature	   of	   the	   water	  surrounding	  them	  (Rijkers	  1982,	  Koppenheffer	  1987).	  	  By	  using	  immune	  related	  biomarkers	  in	  ecotoxicological	  studies,	  some	  insight	  can	  hopefully	  be	  provided	  into	  how	  the	  immune	  system	  in	  marine	  species	  is	  affected	  by	  pollutants.	  Even	  though	  knowledge	  of	  the	  immune	  system	  in	  fish	  has	  grown	  during	  the	  last	  years,	  as	  of	  now,	  there	  is	  still	  limited	  understanding	  of	  the	  degree	  to	  which	  exposure	  to	  environmental	  pollutants	  leads	  to	  modulation	  of	  the	  immune	  system	  in	  marine	  fish	  species	  in	  aquaculture.	  Due	  to	  this,	  the	  understanding	  of	  how	  resistance	  to	  diseases	  is	  affected	  by	  environmental	  pollutants	  is	  correspondingly	  inadequate	  (Segner	  et	  al.	  2012).	  Since	  modulation	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of	  the	  immune	  system	  is	  an	  important	  parameter	  essential	  for	  fish	  populations,	  the	  area	  needs	  to	  be	  studied	  further.	  Perhaps	  one	  reason	  that	  there	  is	  still	  a	  lack	  of	  knowledge	  in	  this	  area	  is	  due	  to	  the	  complexity	  of	  the	  immune	  system,	  and	  the	  fact	  that	  immunotoxic	  effects	  need	  to	  be	  determined	  by	  specific	  techniques	  and	  endpoints.	  	  It	  is	  important	  to	  choose	  the	  right	  parameters	  and	  determine	  how	  the	  meaning	  of	  these	  may	  represent	  the	  individual’s	  entire	  immunocompetence	  (Segner	  et	  al.	  2012).	  International	  groups	  have	  investigated	  the	  effects	  of	  oil	  pollution,	  and	  the	  effects	  of	  PAHs	  in	  various	  fish	  species.	  	  One	  such	  study	  investigated	  the	  effects	  of	  oils	  (heavy	  fuel	  oil	  and	  light	  cycle	  oil)	  and	  pure	  PAHs	  on	  humoral	  immune	  parameters	  (lysozyme	  concentration	  and	  complement	  activity)	  in	  European	  sea	  bass,	  and	  demonstrated	  that	  several	  of	  them	  were	  modulating	  these	  immune	  parameters	  (Bado-­‐Nilles	  et	  al.	  2009).	  Moreover,	  a	  recent	  study	  has	  further	  linked	  exposure	  to	  light	  cycle	  oils	  with	  inflammatory	  phenomena	  in	  the	  same	  species	  (Bodo-­‐Nilles	  et	  al.	  2011).	  A	  study	  on	  acute	  effects	  of	  oil	  exposure,	  also	  in	  European	  sea	  bass,	  showed	  similar	  results,	  as	  well	  as	  indicating	  that	  even	  after	  a	  recovery	  period	  in	  clean	  sea	  water,	  contaminated	  fish	  still	  contained	  levels	  of	  substances	  such	  as	  naphthalene	  and	  benzo[a]pyrene	  high	  enough	  to	  pose	  a	  risk	  for	  human	  consumption	  (Danion	  et	  al.	  2011).	  	  Adverse	  effects	  have	  also	  been	  demonstrated	  in	  other	  species	  such	  as	  in	  zebrafish	  (Danio	  rerio)	  exposed	  to	  produced	  water	  (a	  waste	  from	  oil	  and	  gas	  production	  that	  contains	  oil	  derived	  substances	  such	  as	  PAHs).	  These	  showed	  effects	  in	  several	  vital	  systems	  (nervous,	  respiratory	  and	  immune	  system)	  as	  well	  as	  possible	  reduction	  in	  gene	  transcription	  and	  other	  adverse	  effects	  (Holth	  et	  al.	  2008).	  Many	  of	  the	  same	  results	  were	  also	  apparent	  in	  juvenile	  Atlantic	  cod	  exposed	  to	  oil	  and	  produced	  water,	  in	  a	  treatment	  that	  resulted	  in	  significantly	  induced	  protein	  changes	  even	  at	  low	  levels	  (Bohne-­‐Kjersem	  et	  al.	  2009).	  A	  study	  of	  PAHs	  effects	  on	  an	  endangered	  species	  of	  salmon	  (Chinook	  salmon)	  suggested	  that	  PAHs	  in	  the	  food	  chain	  are	  a	  potential	  source	  of	  injury	  to	  organisms	  (Yanagida	  et	  al.	  2012).	  The	  project	  of	  this	  thesis	  has	  focused	  on	  how	  oil	  pollution	  affects	  both	  biotransformation	  and	  immune	  responses	  in	  juvenile	  Atlantic	  cod.	  It	  was	  coordinated	  with	  another	  project	  set	  to	  begin	  simultaneously:	  the	  MSc-­‐project	  of	  Audun	  Storset,	  which	  looked	  into	  the	  same	  effects	  on	  the	  species	  turbot.	  This	  should	  allow	  for	  interspecies	  comparisons.	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1.3	  Experimental	  species	  
	  The	  species	  chosen	  for	  the	  study	  was	  juvenile	  Atlantic	  cod	  (Gadus	  morhua),	  obtained	  from	  Aquaculture	  Research	  Station,	  Marine	  Research	  Institute,	  S	  Grindavik,	  Iceland.	  Throughout	  its	  lifecycle	  it	  can	  be	  found	  in	  several	  different	  habitats,	  its	  lifecycle	  involves	  spawning	  periods	  in	  the	  first	  quarter	  of	  the	  year	  until	  spring	  season	  starts	  around	  April	  (Brander	  1994).	  The	  eggs	  are	  planktonic	  and	  take	  1-­‐3	  weeks	  to	  spawn.	  Larvae	  diet	  consists	  of	  zooplankton	  until	  a	  larger	  juvenile	  stage	  is	  reached	  where	  the	  diet	  then	  expands	  to	  also	  involve	  larger	  zooplankton	  such	  as	  small	  crustaceans	  like	  shrimp	  as	  well	  as	  worms	  (Hop	  et	  al.	  1992).	  The	  juvenile	  cod	  reach	  a	  mature	  stage	  when	  they	  are	  3-­‐4	  years	  old	  and	  the	  spawning	  cycle	  may	  start	  again.	  At	  the	  mature	  stage	  the	  Atlantic	  cod	  could	  be	  classified	  as	  a	  top	  predator	  with	  a	  diet	  that	  includes	  several	  species	  of	  forage	  fish	  in	  addition	  to	  previously	  mentioned	  organisms	  (Köster	  et	  al.	  2001).	  	  
	   	  
Figure	  1.1	  Lifecycle	  of	  the	  Atlantic	  cod,	  image	  used	  with	  permission	  from	  artist	  
(PISCO	  2011).	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1.4	  Aims	  
	  The	  project	  aimed	  to	  quantify	  biomarker	  responses	  in	  cod	  exposed	  to	  the	  WAF	  of	  NSC	  oil,	  as	  well	  as	  to	  identify	  selected	  immune	  responses	  in	  cod	  (Gadus	  morhua).	  The	  project	  also	  aimed	  to	  quantify	  the	  effect	  of	  a	  pathogen	  (challenge)	  on	  the	  same	  species	  following	  exposure	  to	  the	  water-­‐soluble	  fraction	  of	  crude	  oil.	  	  	  	  The	  overall	  goals	  of	  the	  project	  and	  the	  null	  hypotheses	  related	  to	  each	  goal	  were	  as	  follows:	  	   1) Quantify	  biomarker	  responses	  for	  exposure	  to	  oil	  and	  PAHs	  and	  the	  response	  pattern	  1.1) Quantifying	  EROD	  activity	  for	  different	  treatment	  levels	  and	  exposure	  times.	  	  
H0:	  Hepatic	  EROD	  activity	  is	  not	  treatment	  related.	  
H0:	  Hepatic	  EROD	  activity	  is	  the	  same	  for	  each	  treatment	  at	  different	  
exposure	  periods.	  	  1.2) Quantifying	  CYP1A	  levels	  for	  different	  treatment	  levels	  and	  exposure	  times.	  	  
H0:	  Hepatic	  CYP1A	  protein	  levels	  are	  not	  treatment	  related.	  
H0:	  Hepatic	  CYP1A	  protein	  levels	  are	  the	  same	  for	  each	  treatment	  at	  
different	  exposure	  periods	  (there	  is	  no	  effect	  of	  varied	  exposure	  
time).	  	  1.3) Quantifying	  PAH	  metabolites	  in	  bile	  for	  different	  treatment	  levels	  and	  exposure	  times.	  	  
H0:	  PAH	  metabolite	  levels	  in	  bile	  are	  not	  treatment	  related.	  
H0:	  PAH	  metabolite	  levels	  in	  bile	  are	  the	  same	  for	  each	  treatment	  at	  
different	  exposure	  periods	  (there	  is	  no	  effect	  of	  varied	  exposure	  
time).	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2) Investigating	  how	  oil	  exposure	  affects	  amount	  of	  DNA	  damage	  in	  leukocytes.	  	  
H0:	  There	  is	  no	  difference	  in	  DNA	  damage	  between	  treated	  groups.	  
H0:	  DNA	  damage	  is	  not	  related	  to	  exposure	  period	  (there	  is	  no	  effect	  
of	  different	  exposure	  times).	  	  3) Quantify	  immune	  responses	  following	  exposure	  to	  water-­‐soluble	  components	  of	  crude	  oil.	  
H0:	  There	  will	  be	  no	  differences	  in	  H2O2	  production	  between	  PMA	  
stimulated	  and	  non-­‐stimulated	  leukocytes.	  
H0:	  There	  will	  be	  no	  treatment	  related	  effects	  on	  leukocyte	  H2O2	  
production.	  
H0:	  Treatment	  effects	  related	  to	  leukocytes	  ability	  to	  handle	  
oxidative	  stress	  will	  be	  the	  same	  at	  each	  exposure	  period	  (there	  is	  no	  
effect	  of	  varied	  exposure	  time).	  	   4) Determine	  if	  the	  immunocompetence	  changes	  after	  exposure	  to	  the	  WAF	  of	  oil	  by	  a	  challenge	  (pathogen).	  
H0:	  There	  will	  be	  no	  effect	  of	  injection	  in	  biomarkers	  or	  immune	  responses.	  	   5) Investigate	  species	  differences	  in	  biotransformation	  and	  immune	  responses	  between	  Atlantic	  cod	  (Gadhus	  morhua)	  and	  turbot	  
(Scophthalmus	  maximus).	  
H0:	  There	  will	  be	  no	  species	  differences	  between	  Atlantic	  cod	  (Gadhus	  
morhua)	  and	  turbot	  (Scophthalmus	  maximus).	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2	  Materials	  and	  Methods	  
2.1	  Exposure	  conditions	  	  The	  experiments	  were	  conducted	  at	  the	  Marine	  University	  Centre	  in	  Sandgerði,	  Iceland.	  The	  North	  Atlantic	  and	  the	  Arctic	  Oceans	  that	  surround	  Iceland	  are	  naturally	  clean	  and	  have	  low	  background	  levels	  of	  PAHs	  compared	  to	  the	  Baltic	  Sea	  (Witt	  1995,	  Lohmann	  et	  al.	  2009).	  The	  seawater	  is	  pumped	  from	  a	  borehole	  extending	  20	  m.	  into	  the	  ground	  and	  is	  naturally	  filtered	  through	  the	  porous	  lava.	  It	  is	  aerated	  upon	  arrival	  at	  the	  marine	  station	  and	  is	  free	  from	  particles	  and	  anthropogenic	  material	  (Halldórsson	  2014)	  
	  Juvenile	  Atlantic	  cod	  (Gadus	  morhua)	  was	  obtained	  from	  Aquaculture	  Research	  Station,	  Marine	  Research	  Institute,	  Grindavik,	  Iceland.	  	  	  During	  the	  exposure	  experiment,	  the	  fish	  were	  fed	  with	  small	  pieces	  of	  defrosted	  shrimp	  following	  a	  feeding	  schedule	  where	  the	  animals	  were	  fed	  until	  2	  days	  prior	  to	  sampling.	  The	  animals	  were	  starved	  during	  the	  last	  2	  days	  before	  each	  sampling	  to	  avoid	  emptying	  of	  the	  bile.	  	  	  
2.2	  Experiment	  setup	  	  The	  fish	  were	  exposed	  to	  three	  different	  concentrations	  of	  the	  water-­‐soluble	  fraction	  of	  North	  Sea	  crude	  oil	  (n=6).	  The	  control	  group	  (n=6)	  was	  kept	  in	  clean	  seawater	  that	  flowed	  through	  the	  same	  type	  of	  column	  as	  the	  exposed	  groups.	  The	  tanks	  were	  20L,	  whole-­‐glass	  aquaria	  measuring	  23	  x	  36	  x	  26	  cm.	  	  Each	  tank	  contained	  4	  cod,	  giving	  an	  overall	  number	  of	  96	  fish	  used	  for	  the	  experiment.	  As	  the	  project	  was	  coordinated	  with	  the	  M.Sc.	  projects	  of	  Audun	  Storset	  and	  Ásdís	  Ólafsdóttir,	  each	  tank	  also	  contained	  4	  juvenile	  turbot	  (Scophthalmus	  maximus)	  and	  6	  blue	  mussels	  (Mytilus	  edulis). Additionally,	  8	  fish	  were	  sampled	  as	  0-­‐samples	  before	  the	  experiment	  started.	  These	  were	  acclimated	  and	  fed	  the	  same	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way	  as	  the	  fish	  used	  in	  the	  experiment,	  but	  were	  sampled	  from	  a	  larger	  main	  tank.	  	  
Table	  1.1	  The	  various	  treatments	  used	  with	  their	  relative	  concentration	  of	  NSC	  oil.	  	  	  
Treatment	  	   Concentration	  Control	   0	  g	  NSC	  kg-­‐1	  gravel	  Low	   6	  g	  NSC	  kg-­‐1	  gravel	  Medium	   12	  g	  NSC	  kg-­‐1	  gravel	  High	   24	  g	  NSC	  kg-­‐1	  gravel	  	  The	  oil	  was	  pre-­‐treated	  by	  mixing	  it	  with	  the	  solvent	  dichloromethane	  (DCM)	  and	  water	  on	  a	  magnetic	  stirrer	  for	  24	  h	  to	  simulate	  weathering	  (Holth	  et	  al.	  2014).	  Gravel	  was	  spread	  out	  and	  treated	  with	  the	  appropriate	  amount	  of	  oil	  using	  and	  then	  left	  to	  dry	  for	  24	  h	  (table	  1).	  The	  gravel	  was	  then	  filled	  into	  cylinders	  (d	  x	  h:	  75	  x	  350	  mm)	  and	  each	  one	  connected	  to	  a	  tank	  that	  would	  then	  be	  connected	  to	  the	  flow-­‐through	  system	  where	  the	  input	  flow	  of	  clean	  seawater	  was	  set	  to	  200	  mL	  min-­‐1	  and	  the	  exposure	  flow	  set	  to	  50	  mL	  min-­‐1.	  The	  exposure	  flow	  was	  led	  by	  tubes	  from	  the	  pumps	  and	  through	  the	  relative	  column	  associated	  with	  each	  tank.	  Together	  the	  input	  of	  clean	  and	  contaminated	  water	  was	  thus	  250	  mL	  min-­‐1.	  The	  flow	  of	  water	  into	  the	  tanks	  was	  measured	  twice	  a	  week	  to	  ensure	  stable	  exposure	  conditions	  throughout	  the	  experiment.	  Seawater	  was	  pumped	  through	  the	  cylinders	  and	  into	  the	  tanks.	  The	  tubes	  connected	  to	  the	  peristaltic	  pumps	  were	  inspected	  for	  leaks	  every	  day.	  Samples	  were	  taken	  after	  2,	  8	  and	  16	  days	  of	  exposure.	  
	  
2.3	  Sampling	  	  Each	  fish	  was	  carefully	  removed	  from	  its	  tank,	  and	  euthanized	  by	  a	  sharp	  blow	  to	  the	  head,	  behind	  the	  eyes.	  Fish	  weight	  and	  head-­‐to-­‐tail	  length	  was	  measured	  and	  mucus	  collected	  from	  the	  area	  in	  front	  of	  the	  dorsal	  fin	  using	  a	  cell	  scraper.	  All	  surfaces	  and	  dissection	  tools	  were	  thoroughly	  cleaned	  and	  gloves	  were	  changed	  between	  every	  fish	  sample	  to	  avoid	  cross-­‐contamination.	  Collected	  mucus	  was	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diluted	  in	  5x	  tris-­‐buffer	  in	  a	  cryo-­‐tube	  and	  flash-­‐frozen	  on	  liquid	  nitrogen.	  	  Peripheral	  blood	  (0.2	  mL)	  was	  extracted	  from	  the	  caudal	  vein	  using	  syringes	  prepared	  with	  heparin	  to	  avoid	  blood	  clotting	  within	  the	  syringe	  while	  extracting	  the	  blood.	  After	  extraction,	  the	  cannula	  was	  removed	  and	  the	  blood	  diluted	  in	  0,3	  mL	  cell	  culture	  media	  (CCM)	  that	  was	  prepared	  by	  adjusting	  Leibovitz	  L-­‐15	  medium	  to	  380	  mOsm	  by	  adding	  1.5M	  NaCl,	  then	  adding	  1	  ul	  heparin	  stock	  (10	  kU/mL)	  per	  mL	  osmolality	  adjusted	  L-­‐15	  medium,	  giving	  10	  U/mL,	  which	  again	  had	  10	  uL	  antibiotics	  solution	  added	  pr.	  mL.	  The	  CCM	  would	  then	  contain	  100	  U/mL	  penicillin,	  0.1	  mg/mL	  streptomycin	  and	  0.25	  ug/mL	  amphotericin	  B.	  Tissue	  and	  bile	  samples	  were	  collected	  after	  opening	  the	  abdomen.	  The	  entire	  gall	  bladder	  was	  collected	  in	  an	  eppendorf	  tube,	  using	  a	  surgical	  scissor	  while	  tweezing	  together	  the	  bile	  duct	  to	  avoid	  spillage	  of	  bile	  and	  contamination	  of	  the	  remaining	  organs.	  The	  liver	  was	  then	  excised	  and	  the	  area	  between	  the	  portal	  vein	  entrances	  sampled.	  The	  head	  kidney	  was	  excised	  using	  tweezers	  and	  collected	  by	  ventral	  incision.	  
	  
2.4	  Pathogen	  challenge	  study	  	  After	  13	  days	  of	  exposure	  there	  were	  2	  fish	  remaining	  in	  each	  tank.	  One	  of	  these	  was	  injected	  intraperitoneally	  with	  a	  sham	  pathogen	  (lipopolysaccharide	  LPS).	  The	  amount	  of	  injected	  pathogen	  was	  20	  ul/g	  with	  an	  initial	  concentration	  of	  1	  mg/mL.	  However,	  as	  the	  volume	  required	  relative	  to	  the	  weight	  turned	  out	  to	  be	  quite	  high	  and	  caused	  some	  discomfort	  to	  the	  fish	  (which	  showed	  in	  reduced	  swimming	  ability),	  the	  concentration	  was	  doubled	  to	  2	  mg/mL	  to	  reduce	  the	  volume	  needed	  for	  injection	  to	  10	  ul/g.	  The	  fish	  were	  injected	  carefully	  so	  as	  to	  not	  puncture	  any	  internal	  organs,	  but	  nevertheless	  as	  swiftly	  as	  possible	  to	  reduce	  the	  amount	  of	  stress	  on	  the	  animal.	  	  To	  further	  reduce	  stress,	  the	  head	  region	  of	  the	  fish	  was	  protected	  with	  a	  moist	  cover	  until	  the	  injection	  was	  over.	  For	  detecting	  eventual	  effects	  of	  the	  procedure	  on	  biomarkers,	  the	  remaining	  fish	  were	  injected	  with	  phosphate	  buffered	  saline	  solution	  (PBS)	  using	  the	  same	  approach.	  A	  small	  fin-­‐clip	  was	  done	  on	  the	  dorsal	  fin	  of	  all	  individuals	  injected	  with	  LPS.	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2.5	  Extraction	  of	  leukocytes	  from	  blood	  
	  The	  samples	  of	  diluted	  blood	  were	  layered	  on	  top	  of	  a	  percoll	  gradient	  calculated	  according	  to	  (Sørensen	  et	  al.	  1997,	  Munoz	  et	  al.	  1999,	  Espelid	  et	  al.	  2003,	  Øverland	  et	  al.	  2010).	  The	  gradient	  was	  made	  in	  a	  15	  mL	  Falcon	  centrifugation	  tube	  with	  2,5	  mL	  percoll	  1,070	  	  g/L	  (0.490	  mL	  percoll	  +	  1.5M	  NaCl	  +	  0.410	  mL	  H2O2)	  in	  the	  bottom	  layer	  and	  2,0	  mL	  percoll	  1,050	  g/L	  (0.337	  mL	  percoll	  +	  1.5M	  NaCl	  +	  0.563	  mL	  H2O2)	  in	  the	  upper	  layer,	  making	  the	  total	  volume	  of	  the	  tube	  5	  mL.	  The	  tube	  was	  placed	  in	  a	  swing-­‐out	  rotor	  centrifuge	  and	  centrifuged	  at	  400	  x	  
g	  for	  40	  min.	  at	  room	  temperature.	  	  Leukocytes	  then	  became	  visible	  as	  a	  white	  band	  in	  the	  1.050-­‐1.070	  percoll	  interface	  and	  were	  collected	  using	  a	  plastic	  Pasteur	  pipette,	  transferred	  to	  a	  marked	  eppendorf	  tube	  and	  diluted	  2x	  in	  CCM.	  The	  tubes	  were	  centrifuged	  for	  5	  min.	  at	  400	  x	  g	  in	  room	  temperature.	  A	  pellet	  of	  cells	  was	  obtained	  in	  the	  bottom	  of	  the	  tubes	  and	  was	  resuspended	  in	  1,5	  mL	  CCM.	  	  To	  count	  and	  assess	  viability	  of	  the	  cells,	  15	  μL	  of	  each	  sample	  was	  added	  15	  μL	  Trypan	  blue	  and	  loaded	  onto	  a	  slide	  for	  measurement	  with	  an	  automated	  cell	  counter	  (Invitrogen	  Countess®	  Automated	  Cell	  Counter).	  Samples	  were	  diluted	  to	  1*10^6	  cells/mL	  with	  CCM.	  	  	  
2.6	  Extraction	  of	  leukocytes	  from	  kidney	  	  The	  extracted	  head	  kidney	  tissue	  was	  added	  to	  1	  mL	  CCM,	  which	  was	  minced	  through	  a	  100	  μm	  nylon	  cell	  strainer	  using	  another	  4	  mL	  of	  CCM,	  giving	  a	  total	  volume	  of	  5	  mL	  before	  adding	  the	  suspended	  kidney	  leukocytes	  to	  a	  tube	  with	  the	  same	  percol	  gradient	  as	  previously	  mentioned.	  Following,	  the	  process	  was	  the	  same	  as	  described	  in	  section	  2.5.	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2.7	  Respiratory	  burst	  	  The	  assay	  was	  based	  on	  the	  Invitrogen	  Amplex	  Red	  Hydrogen	  assay,	  where	  peroxidase	  reacts	  with	  the	  added	  substrate	  Ampliflu	  Red	  and	  forms	  the	  very	  fluorescent	  compound	  resorufin.	  H2O2	  stock	  (20	  mM)	  was	  diluted	  to	  10	  uM	  with	  reaction	  buffer	  and	  a	  2x	  dilution	  series	  with	  7	  concentrations	  was	  then	  made.	  The	  2.5	  uM	  (dilution	  no	  3)	  was	  discarded.	  One-­‐hundred	  uL	  blank	  assay	  solution	  (0.1	  U	  mL-­‐1	  HRP	  in	  KRPG-­‐buffer	  containing	  145	  mM	  NaCl,	  4.86	  mM	  KCl,	  5.7	  mM	  NaH2PO4x2H2O,	  0.54	  mM	  CaCl2,	  1.22	  mM	  MgSO4x7H2O,	  5.5	  mM	  glucose	  and	  pH	  adjusted	  to	  7.4)	  was	  added	  to	  wells	  A1-­‐A3	  of	  a	  NUNCLON	  96-­‐well	  microtiter	  plater.	  Assay	  working	  solution	  (50	  uM	  Amplex	  Red;	  0.1	  U	  mL-­‐1	  HRP	  in	  KRPG-­‐buffer	  was	  prepared	  and	  added	  to	  wells	  B1-­‐H3	  and	  rows	  B,	  D,	  F	  and	  H	  on	  the	  microtiter	  plate	  (100	  uL	  in	  each	  well).	  Standard	  curve	  (H2O2	  dilution	  series)	  was	  added	  in	  triplets	  for	  each	  concentration	  in	  wells	  C1-­‐H3	  and	  blank	  (RB)	  was	  in	  wells	  B1-­‐B3.	  	  Twenty	  uL	  of	  samples	  diluted	  to	  1*106	  cells	  mL-­‐1	  with	  CCM	  were	  added	  to	  wells	  A4-­‐H12.	  Each	  sample	  was	  added	  in	  2	  triplets.	  A	  random	  sample	  was	  also	  added	  to	  wells	  A1-­‐A3	  to	  test	  that	  there	  would	  be	  no	  reaction	  when	  Amplex	  Red	  was	  not	  added.	  	  Finally	  an	  assay	  working	  solution,	  containing	  PMA	  (assay	  working	  solution	  +	  0.12	  ug	  PMA	  per	  mL-­‐1)	  was	  added	  to	  rows	  A,	  C,	  E	  and	  G	  (coloumn	  4-­‐12).	  The	  fluorescence	  of	  the	  product	  was	  then	  read	  in	  a	  plate	  reader	  (BioTek	  Synergy	  MX)	  at	  530	  nm/590	  nm.	  	  As	  the	  the	  reactions	  flattened	  out	  after	  15	  min.,	  the	  fluorescence	  was	  read	  immediately	  after	  all	  assay	  components	  were	  added	  to	  the	  plate.	  	  
2.8	  Comet	  assay	  	  After	  dilution,	  10	  μL	  of	  each	  sample	  was	  suspended	  in	  90	  μL	  LMP	  agarose	  (0,75%	  in	  PBS)	  on	  GelBond	  films.	  When	  the	  agarose	  had	  solidified,	  the	  films	  were	  put	  in	  boxes	  containing	  prechilled	  lysis	  buffer	  (2.5	  M	  NaC,	  100	  mM	  Na2	  EDTA,	  10	  mM	  Trizma	  base,	  1%	  Triton	  X-­‐100	  with	  pH	  10)	  at	  4	  °C.	  	  The	  samples	  were	  rinsed	  briefly	  in	  electrophoresis	  buffer	  (300	  mM	  NaOH,	  1	  mM	  EDTA	  with	  pH	  approx.	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13.2)	  for	  unwinding	  and	  denaturation	  of	  DNA.	  The	  samples	  were	  then	  transferred	  to	  a	  fresh	  electrophoresis	  buffer	  in	  the	  electrophoresis	  chamber	  for	  a	  total	  of	  20	  min.	  Horizontal	  electrophoresis	  was	  run	  at	  4°C	  for	  20	  min.	  with	  25V	  applied.	  The	  films	  were	  removed	  and	  rinsed	  in	  a	  neutralisation	  buffer	  (0.4	  M	  Trizma	  base	  in	  dH2O	  adjusted	  to	  pH	  7.5)	  at	  room	  temperature	  and	  then	  stored	  in	  a	  fresh	  neutralisation	  for	  15	  min.	  After	  a	  brief	  rinse	  with	  first	  dH2O	  and	  then	  96%	  ethanol,	  the	  films	  were	  fixed	  for	  a	  minimum	  of	  1	  ½	  hours	  in	  96%	  ethanol	  and	  then	  air	  dried	  for	  storage	  until	  staining	  would	  take	  place.	  	  	  The	  films	  were	  evaluated	  by	  staining	  them	  in	  a	  darkroom	  for	  20	  min.	  using	  50	  mL	  TE-­‐buffer	  	  (10mM	  Tris-­‐Hcl	  with	  PH	  8	  and	  1mM	  EDTA	  with	  pH	  8	  the	  buffer	  was	  finally	  adjusted	  to	  pH	  8	  before	  use) containing	  40	  μL	  SyberGold	  (prediluted	  10.000x	  from	  stock	  in	  DMSO).	  To	  make	  sure	  the	  dye	  was	  distributed	  to	  the	  entire	  film,	  the	  staining	  boxes	  were	  placed	  on	  a	  rocking	  table	  during	  the	  staining	  period.	  	  After	  rinsing	  the	  films	  with	  dH2O,	  they	  were	  placed	  on	  plexi-­‐glass	  plates,	  and	  cover	  slides	  were	  applied	  with	  dH2O,	  while	  avoiding	  air	  bubbles.	  The	  films	  were	  then	  scored	  using	  the	  CometAssay	  IV	  software	  (Perceptive	  Instruments),	  linked	  to	  a	  fluorescence	  microscope	  (Zeiss).	  Scoring	  was	  done	  using	  20x	  magnification	  and	  50	  cells	  were	  scored	  for	  each	  sample.	  	  
2.9	  PAH	  metabolites	  from	  bile	  	  The	  bile	  samples	  were	  stored	  at	  -­‐20°C	  until	  the	  analysis	  commenced,	  at	  which	  point	  they	  were	  thawed	  on	  ice	  in	  the	  dark.	  Twenty	  μL	  of	  extracted	  bile	  was	  pipetted	  and	  mixed	  with	  50	  μL	  dH2O	  in	  a	  small	  eppendorf	  tube.	  The	  weight	  of	  the	  bile	  was	  recorded	  using	  a	  balance	  of	  precision.	  10	  μL	  of	  standard	  (Trifenylamine	  10	  mg	  pr.	  25	  mL	  methanol)	  was	  added	  to	  the	  tube	  and	  the	  weight	  was	  recorded.	  20	  μL	  of	  the	  enzyme	  β-­‐glucuronidase/aryl	  sulphatase	  was	  added	  and	  the	  weight	  was	  recorded.	  The	  samples	  were	  then	  incubated	  for	  60	  min.	  at	  37°C.	  	  To	  stop	  the	  reaction,	  200	  μL	  of	  methanol	  was	  added	  to	  each	  tube,	  and	  the	  contents	  were	  thoroughly	  mixed.	  Samples	  were	  then	  cooled	  on	  ice.	  The	  samples	  were	  centrifuged	  for	  10	  min.	  at	  4°C	  at	  4000	  g.	  The	  supernatant	  from	  each	  tube	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was	  transferred	  to	  HPLC	  tubes	  and	  all	  samples	  were	  analysed	  by	  Merete	  Grung	  at	  NIVA,	  using	  high-­‐performance	  liquid	  chromatography	  (HPLC)	  with	  fluorescence	  detection.	  	  The	  samples	  were	  stored	  at	  -­‐20°C	  until	  analysis.	  The	  HPLC	  analysis	  was	  done	  in	  a	  PAH	  C18	  column	  with	  a	  precoloumn	  (Vydac	  201TP5415,	  5	  µm	  particle	  size,	  4,6x250	  mm).	  Fluorescence	  detection	  was	  done	  at	  wavelengths	  shown	  in	  table	  1.2.	  
 
Table	  1.2	  HPLC	  Fluorescence	  detection;	  excitation	  and	  emission	  for	  metabolites.	  
Metabolite	   Excitation	  nm	   Emission	  nm	  Naphtalene	   325	   358	  Phenatrene	   251	   364	  Pyrene	   246	   384	  B[a]P	   380	   430	  ISD	  picene	   282	   375	  ISD	  trifenylamin	   300	   360	  	  Injection	  volume	  was	  25	  ul	  and	  the	  column	  temperature	  was	  30°C.	  The	  samples	  were	  analysed	  with	  2	  mobile	  phases,	  first	  a	  40:60%	  w/w	  acetonitrile	  and	  water	  and	  second	  a	  100%	  acetonitrile	  mobile	  phase.	  The	  flow	  was	  1	  mL/min	  and	  the	  reservoir	  was	  degassed	  continuously	  with	  helium	  (25	  ml	  min-­‐1)	  during	  the	  analysis.	  The	  tops	  of	  each	  produced	  curve	  was	  used	  to	  quantify	  the	  amount	  of	  metabolite.	  	  
	  
2.10	  Preparation	  of	  cytosolic	  and	  microsomal	  extract	  from	  liver	  
	  The	  frozen	  liver	  samples	  (approx.	  0.1	  g)	  were	  each	  transferred	  to	  a	  2-­‐ml	  tube	  containing	  approx.	  20	  homogenisation	  beads	  (Precellys	  24	  Soft	  Tissue	  homogenizing	  1.4	  mm	  ceramic	  beads,	  Bertin	  Technologies)	  and	  a	  homogenisation-­‐buffer	  (0.1	  M	  NaPO	  buffer,	  0.15M	  KCL,	  1mM	  DTT,	  glycerol	  (5%w/w)	  and	  pH	  adjusted	  to	  7.8).	  The	  liver	  was	  then	  homogenized	  in	  a	  Precellys	  homogenizer	  (Bertin	  Technologies).	  The	  machine	  was	  set	  up	  to	  run	  3	  rounds	  of	  10	  sec.	  each	  at	  6000	  rpm	  with	  5	  sec.	  break	  between	  each	  round.	  Sample	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temperature	  was	  kept	  stable	  at	  4°C	  by	  pumping	  cold	  air,	  cooled	  by	  liquid	  nitrogen	  onto	  the	  samples	  using	  a	  Cryolys	  cooler	  (Bertin	  Technologies).	  The	  homogenized	  samples	  were	  transferred	  to	  eppendorf	  tubes,	  while	  at	  the	  same	  time	  removing	  the	  plastic	  beads	  from	  the	  sample	  by	  pipetting.	  	  The	  samples	  were	  centrifuged	  for	  30	  min.	  at	  4°C	  at	  10.000	  g	  in	  a	  Heareus	  Multifuge	  3	  S-­‐R	  centrifuge.	  	  Using	  a	  Pasteur	  glass	  pipette,	  the	  fatty	  layer	  was	  carefully	  penetrated	  and	  the	  supernatant	  was	  collected	  and	  transferred	  to	  a	  centrifugation	  tube.	  The	  supernatant	  was	  centrifuged	  for	  60	  min.	  at	  4°C	  at	  a	  speed	  of	  100.000	  x	  g	  (Thermo	  Scientific	  Sorvall	  mTX150	  Micro-­‐Ultrasentrifuge). The	  supernatant	  was	  removed	  and	  the	  microsomal	  pellet	  transferred	  to	  an	  eppendorf	  tube	  along	  with	  200	  μL	  of	  microsomal	  buffer	  (0.1	  M	  NaPO	  buffer	  with	  glycerol	  (20%	  w/w)	  added	  and	  pH	  adjusted	  to	  7.5).	  The	  sample	  was	  then	  homogenized	  using	  a	  pellet	  pestle.	  For	  each	  sample,	  30	  μL	  was	  collected	  for	  ELISA	  analysis,	  30	  μL	  was	  collected	  for	  protein	  quantification	  and	  at	  least	  60	  μL	  was	  collected	  for	  EROD	  analysis.	  	  	  	  
2.11	  Protein	  analysis	  	  
	  Samples	  were	  defrosted	  from	  -­‐80°C	  and	  diluted	  with	  0.1M	  Tris	  buffer	  (pH	  8.0	  at	  4°C).	  BSA	  standard	  (bovine	  gamma	  globuline	  protein	  standard)	  15	  mg/mL	  was	  also	  defrosted	  from	  -­‐80°C	  and	  diluted	  to	  1000	  μg/mL	  with	  0.1M	  Tris	  buffer.	  A	  2x	  dilution	  series	  was	  included,	  and	  a	  reference	  sample	  of	  approx.	  0,4	  μg/mL	  was	  included	  in	  all	  analyses.	  All	  work	  was	  done	  on	  ice.	  Four	  replicates	  of	  blank	  	  (0.1M	  Tris	  buffer),	  3	  replicates	  of	  each	  standard,	  3	  replicates	  of	  each	  diluted	  sample	  and	  3	  replicates	  of	  reference	  sample	  were	  then	  pipetted	  onto	  a	  96	  well	  microtiter	  plate	  with	  10	  μL	  in	  each	  well.	  	  Twenty-­‐five	  μL	  of	  room-­‐tempered	  reagent	  A	  (BioRad	  (kit.	  No.	  5000-­‐0111))	  was	  then	  pipetted	  into	  all	  wells,	  using	  a	  multipipette.	  Next,	  200	  μL	  of	  reagent	  B	  was	  pipetted	  into	  all	  wells.	  The	  plate	  was	  gently	  agitated	  by	  hand	  and	  set	  to	  incubate	  at	  room	  temperature	  for	  15	  minutes.	  After	  the	  incubation	  period,	  absorbance	  was	  read	  at	  750	  nm	  using	  a	  BioTek	  Synergy	  MX	  plate	  reader	  and	  the	  Gen	  5	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software	  (ver.	  4.0).	  Samples	  outside	  the	  standard	  curve	  were	  diluted	  further	  and	  reanalysed.	  	  	  
2.12	  Ethoxyresorufin	  O-­‐deethylase	  (EROD)	  activity	  	  	  Microsomes	  were	  diluted	  on	  ice	  in	  0.1M	  potassium	  phosphate	  buffer	  (pH	  8.0)	  to	  1	  mg/mL	  protein	  for	  EROD	  analysis.	  The	  reaction	  solution	  was	  prepared	  at	  room	  temperature	  in	  the	  dark	  (as	  both	  7-­‐ethoxyresorufin	  and	  resorufin	  are	  light	  sensitive)	  using	  30	  mL	  KPO-­‐buffer	  (0.1M,	  pH	  8.0)	  and	  180	  uL	  0.5mM	  7-­‐ethoxyresorufin	  (in	  DMSO).	  The	  standard	  (1mM	  resorufin	  in	  DMSO)	  was	  defrosted	  from	  -­‐20°C,	  and	  diluted	  to	  0.64	  μM	  in	  two	  steps	  (first	  100x	  to	  10	  μM	  in	  potassium	  phosphate	  buffer,	  then	  to	  0.64	  μM	  in	  reaction	  solution).	  The	  0.64	  μM	  standard	  was	  then	  further	  diluted	  in	  a	  2x	  dilution	  series	  to	  give	  the	  following	  concentration	  series:	  0.64,	  0.32,	  0.16,	  0.08,	  0,04,	  0.02,	  0.01	  and	  0.00.	  Eight	  replicates	  (50	  ul)	  of	  potassium	  phosphate	  buffer	  (blank)	  were	  distributed	  to	  a	  NUNC	  96-­‐well	  microtiter	  plate	  (Thermo	  Scientific).	  Resourufin-­‐standards	  were	  then	  pipetted	  in	  duplicates	  to	  the	  plate	  (75	  μL	  was	  added	  to	  each	  well).	  Diluted	  samples	  and	  reference	  samples	  (cod	  samples	  from	  the	  M.sc.	  project	  of	  Lene	  Fredriksen	  that	  had	  been	  diluted	  10x)	  were	  then	  pipetted	  onto	  the	  plates	  with	  6	  replicates	  for	  each	  sample,	  50	  μL	  in	  each	  well.	  Three	  replicates	  of	  each	  sample	  and	  reference	  then	  had	  10	  μL	  0,32	  μM	  resorufin	  added	  to	  them.	  Reaction	  solution	  was	  distributed	  to	  all	  wells	  (200	  μL)	  except	  for	  wells	  containing	  resorufin	  standards.	  The	  reaction	  was	  started	  by	  the	  addition	  of	  NADPH	  solution	  (2,4	  mM	  NADPH	  diluted	  in	  potassium-­‐phosphate	  buffer),	  25	  μL	  per	  well.	  Fluorescence	  was	  read	  in	  a	  platereader	  (BioTek	  Synergy	  MX)	  immediately	  thereafter	  with	  the	  following	  settings:	  Excitation	  530	  nm,	  emission	  590	  nm,	  with	  20	  nm	  slit	  width	  and	  optics	  position	  set	  to	  “top”.	  Sensitivity	  was	  automatically	  related	  to	  the	  fluorescence	  of	  the	  highest	  concentration	  of	  resorufin	  and	  the	  plate	  reader	  (BioTek	  Synergy	  MX)	  was	  set	  to	  shake	  for	  10	  sec	  at	  medium	  intensity	  before	  the	  first	  kinetic	  read.	  There	  were	  a	  total	  of	  8	  read	  intervals	  and	  the	  total	  read	  time	  was	  5	  min.	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2.13	  Concentration	  of	  CYP1A	  	  Liver	  microsomes	  were	  diluted	  to	  10	  μg	  protein/mL	  in	  carbonate-­‐bicarbonate	  buffer	  (0.05M,	  pH	  9.6	  at	  25°C).	  One	  hundred	  μL	  of	  coating	  buffer	  were	  pipetted	  into	  all	  wells	  in	  the	  1st	  column	  of	  the	  plates.	  4	  of	  these	  would	  later	  have	  primary	  antibody	  added	  to	  them	  while	  the	  rest	  would	  be	  left	  with	  no	  primary	  antibody	  to	  monitor	  non-­‐specific	  binding.	  4	  replicates	  of	  each	  diluted	  sample	  were	  then	  distributed	  to	  4	  wells	  on	  a	  96-­‐well	  microtiter	  plate,	  with	  100	  μL	  in	  each	  well.	  	  Additionally,	  a	  reference	  sample	  was	  added	  with	  4	  replicates	  (each	  containing	  100	  μL).	  The	  plate	  was	  incubated	  overnight	  at	  4°C	  with	  tape	  covering	  each	  well	  to	  avoid	  evaporation.	  	  On	  day	  2	  the	  plate	  was	  washed	  (using	  the	  Scanwasher	  300)	  on	  a	  setting	  that	  washed	  out	  the	  plate	  3	  times	  with	  TTBS	  consisting	  of	  20mM	  Tris-­‐buffer	  pH	  8.5	  with	  0.5M	  NaCl	  all	  diluted	  in	  10	  L	  dH2O	  with	  5	  mL	  Tween-­‐20	  added.	  A	  blocking	  solution	  (TTBS	  with	  1%	  w/w	  BSA)	  was	  then	  added	  to	  all	  wells	  (300	  μL	  in	  each	  well)	  and	  set	  to	  incubate	  for	  60	  min.	  at	  room	  temperature.	  The	  plate	  was	  washed	  another	  3x	  before	  primary	  antibody	  (rabbit	  anti-­‐fish	  CYP1A	  antibody	  diluted	  1:1000	  in	  antibody	  buffer	  containing	  TTBS	  with	  0.1%	  w/w	  BSA)	  was	  pipetted	  to	  all	  wells	  (100	  μL	  in	  each	  well)	  containing	  samples.	  The	  primary	  antibody	  was	  also	  distributed	  to	  the	  4	  replicates	  in	  the	  first	  column	  of	  the	  plate.	  	  The	  ScanWasher	  300	  aspirated	  all	  liquid	  from	  the	  plate	  so	  the	  antibody	  was	  added	  to	  empty,	  but	  coated	  wells.	  The	  plate	  was	  then	  set	  to	  incubate	  overnight	  at	  4°C	  with	  tape	  as	  per	  the	  first	  day.	  	  After	  the	  overnight	  incubation,	  plates	  were	  recovered	  from	  4°C	  and	  washed	  3x	  with	  the	  Scanwasher	  300	  using	  TTBS.	  100	  μL	  of	  diluted	  (1:3000	  in	  antibody	  buffer)	  secondary	  antibody	  (goat	  anti-­‐rabbit	  GAR-­‐HRP)	  was	  added	  to	  all	  wells.	  	  The	  plates	  were	  then	  set	  to	  incubate	  for	  7	  ½	  hours	  at	  4°C	  with	  tape	  covering	  them.	  After	  the	  incubation	  period	  plates	  were	  washed	  5x.	  One	  hundred	  μL	  of	  colouring	  buffer	  (TMB)	  was	  added	  to	  all	  wells	  in	  a	  darkroom	  and	  the	  plates	  were	  incubated	  at	  room	  temperature	  until	  colour	  developed	  (this	  took	  18	  min.).	  When	  an	  appropriate	  amount	  of	  colour	  had	  developed,	  the	  reaction	  was	  stopped	  by	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adding	  100	  ul	  0.18M	  H2SO4	  to	  all	  wells.	  The	  absorbance	  was	  read	  in	  the	  plate	  reader	  (BioTek	  Synergy	  MX)	  at	  450	  nm.	  	  	  	  
2.15	  Statistical	  Analyses	  	  Results	  were	  analysed	  using	  a	  set	  of	  rules	  that	  were	  followed	  consequently.	  All	  data	  was	  log10	  transformed	  for	  continuity	  in	  the	  data	  representation	  and	  easier	  comparison	  between	  groups.	  	  Performing	  a	  Levene’s	  test	  assessed	  the	  variances	  in	  the	  data.	  This	  is	  a	  statistical	  test	  where	  the	  hypothesis	  is	  that	  the	  variance	  in	  the	  data	  is	  equal.	  If	  the	  p-­‐value	  of	  this	  test	  is	  significant	  (<0,05),	  it	  means	  that	  the	  variance	  is	  not	  equal	  and	  measures	  must	  be	  taken	  to	  achieve	  equal	  variances.	  When	  this	  was	  not	  possible,	  it	  was	  necessary	  to	  run	  a	  non-­‐parametric	  analysis	  (Kruskal-­‐Wallis	  test).	  In	  most	  cases,	  however,	  the	  already	  transformed	  data	  had	  equal	  variance	  so	  a	  parametric	  one-­‐way	  ANOVA	  could	  be	  run,	  comparing	  treated	  groups	  to	  the	  control	  group.	  Should	  there	  be	  a	  significant	  difference	  between	  these,	  a	  Dunnett’s	  test	  could	  be	  run	  additionally	  to	  assess	  
which	  treatment	  groups	  were	  significantly	  different	  from	  the	  control.	  In	  the	  case	  of	  the	  respiratory	  burst	  assay,	  there	  was	  more	  than	  one	  parameter,	  so	  a	  two-­‐way	  ANOVA	  was	  used.	  Statistical	  analyses	  were	  performed	  using	  JMP	  (version	  11.0	  by	  SAS	  Institute	  Inc)	  software	  and	  graphs	  were	  made	  using	  GraphPad	  PRISM	  (version	  6.0).	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3	  Results	  
3.1	  Size	  and	  Weight	  The	  fish	  were	  weighed	  and	  their	  head-­‐to-­‐tail	  length	  measured	  and	  recorded	  for	  reference.	  Average	  weight	  was	  30.8	  g	  and	  average	  length	  was	  15.6	  cm.	  
3.2	  Hepatic	  7-­‐ethoxyresorufin-­‐O-­‐deethylase	  (EROD)	  Activity	  Control	  groups	  for	  all	  exposure	  days	  (with	  the	  control	  for	  16	  days	  split	  into	  2	  groups,	  one	  injected	  with	  LPS	  and	  the	  other	  injected	  with	  PBS)	  were	  tested	  against	  the	  zero	  samples.	  As	  Levene’s	  test	  showed	  equal	  variances,	  each	  control	  group	  was	  tested	  against	  the	  zero	  samples	  with	  a	  one-­‐way	  ANOVA.	  None	  of	  the	  control	  groups	  were	  significantly	  different	  from	  the	  zero	  samples	  (p-­‐value	  =	  0.9617).	  	  R2	  for	  the	  test	  was	  0.028.	  	  
Figure	  3.1	  Control	  groups	  for	  2,	  8,	  16	  days	  with	  LPS	  and	  16	  days	  with	  PBS	  
compared	  to	  zero	  samples;	  median,	  quartiles,	  minimum	  and	  maximum.	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Following	  2	  days	  of	  exposure,	  the	  Levene’s	  test	  showed	  equal	  variances	  (p-­‐value	  =	  0.2942)	  so	  a	  one-­‐way	  ANOVA	  was	  run	  yielding	  a	  significant	  p-­‐value	  (p-­‐value	  =0.0284*).	  	  A	  Dunnett’s	  test	  showed	  that	  the	  low	  (p-­‐value	  =	  0.0160*)	  and	  medium	  (p-­‐value	  =	  0.0415*)	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  group.	  R2	  for	  the	  test	  was	  0.358.	  	  The	  data	  for	  8	  days	  of	  exposure	  had	  equal	  variances,	  and	  a	  one-­‐way	  ANOVA	  was	  done.	  The	  ANOVA	  had	  a	  significant	  Prob	  >	  F	  value	  (p-­‐value	  =	  <	  0.0001*)	  which	  indicated	  a	  significant	  difference	  between	  treated	  groups	  and	  the	  control	  group.	  A	  Dunnett’s	  test	  showed	  that	  all	  treatment	  groups	  had	  significant	  p-­‐values	  (low:	  <	  0.0001*,	  medium:	  0.0003*	  and	  high:	  0.0008*).	  R2	  for	  the	  test	  was	  0.645.	  For	  the	  16	  days	  exposure	  injected	  groups	  were	  analysed	  separately,	  as	  one	  group	  had	  been	  injected	  with	  LPS	  and	  the	  other	  with	  PBS.	  	  For	  the	  LPS	  group,	  the	  Levene’s	  test	  showed	  that	  the	  data	  had	  equal	  variances	  so	  a	  one-­‐way	  ANOVA	  was	  done.	  The	  test	  statistic	  for	  the	  ANOVA	  showed	  a	  significant	  test	  statistic	  (p-­‐value	  =	  0.0477*)	  and	  a	  Dunnett’s	  test	  indicated	  that	  the	  High	  treatment	  group	  was	  significantly	  different	  from	  the	  control	  group	  (p-­‐value	  =	  0.0393*).	  R2	  for	  the	  test	  was	  0.445.	  	  The	  PBS	  injected	  group	  showed	  equal	  variances	  in	  the	  data	  on	  the	  Levene’s	  test.	  The	  one-­‐way	  ANOVA	  was	  not	  significant	  (p-­‐value	  =	  0.1448)	  and	  indicated	  no	  differences	  in	  the	  treatment	  groups	  relative	  to	  the	  control	  group.	  R2	  for	  the	  test	  was	  0.330.	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Figure	  3.2	  EROD	  activity	  in	  cod	  exposed	  to	  treatment	  groups	  for	  all	  exposure	  
times	  (2,	  8	  and	  16	  days).	  Results	  for	  16	  days	  of	  exposure	  depicted	  with	  only	  LPS	  
injected	  samples,	  and	  only	  PBS	  injected	  samples.	  Graph	  shows	  medians,	  quartiles,	  
minimum	  and	  maximum.	  Asterisks	  indicate	  treatment	  groups	  with	  significant	  (	  <	  
0.0500)	  p-­‐values.	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3.3	  Concentration	  of	  CYP1A	  
	  Control	  groups	  for	  all	  exposure	  days	  were	  tested	  against	  the	  zero	  samples	  with	  a	  one-­‐way	  ANOVA	  after	  a	  Levene’s	  test	  had	  showed	  equal	  variances	  in	  the	  data.	  The	  ANOVA	  was	  not	  significant	  (p-­‐value	  =	  0.9403),	  showing	  that	  none	  of	  the	  control	  groups	  were	  significantly	  different	  from	  the	  zero	  samples.	  	  R2	  for	  the	  test	  was	  0.030.	  	  
	  For	  2	  days	  of	  exposure	  the	  Levene’s	  test	  showed	  equal	  variance.	  A	  one-­‐way	  ANOVA	  was	  used	  to	  compare	  the	  treated	  groups	  against	  the	  control.	  The	  ANOVA	  was	  significant	  (p-­‐value	  =	  0.0024*)	  and	  a	  Dunnet’s	  test	  showed	  that	  the	  low	  (p-­‐value	  =	  0.0035*)	  and	  the	  high	  (p-­‐value	  =	  0.0017*)	  treatment	  groups	  were	  significantly	  different	  than	  the	  control	  group.	  R2	  for	  the	  test	  was	  0.505.	  The	  data	  for	  8	  days	  of	  exposure	  showed	  equal	  variance	  with	  Levene’s	  test	  and	  a	  one-­‐way	  ANOVA	  further	  showed	  that	  there	  was	  a	  significant	  difference	  between	  
Figure	  3.3	  CYP1A	  concentrations	  in	  control	  groups	  for	  all	  exposure	  times	  
compared	  to	  the	  zero-­‐samples	  group.	  Graph	  shows	  medians,	  quartiles,	  minimum	  
and	  maximum.	  
	   22	  
treatment	  groups	  and	  the	  control	  (p-­‐value	  =	  <0.0001*).	  A	  Dunnett’s	  test	  revealed	  significant	  p-­‐values	  in	  all	  treatment	  groups	  (low:	  0.0014*,	  medium:	  0.0004*	  and	  high:	  <0.0001*).	  R2	  for	  the	  test	  was	  0.66.	  	  The	  PBS	  injected	  group	  exposed	  for	  16	  was	  used	  to	  represent	  the	  16	  days	  of	  exposure	  group.	  Levene’s	  test	  showed	  equal	  variances	  so	  a	  one-­‐way	  ANOVA	  was	  performed,	  and	  showed	  a	  significant	  treatment	  effect	  (p-­‐value	  =	  0.0046*).	  Dunnet’s	  test	  further	  showed	  that	  all	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  group	  (p-­‐values	  =	  0.0172*,	  0.0031*	  and	  0.0137*	  for	  low,	  medium	  and	  high	  treatment	  group	  respectively).	  R2	  for	  the	  test	  was	  0.621.  	  For	  16	  days	  of	  exposure	  and	  injected	  with	  LPS,	  the	  Levene’s	  test	  showed	  equal	  variances	  in	  the	  data.	  A	  one-­‐way	  ANOVA	  gave	  a	  significant	  test	  value	  (p-­‐value	  =	  0.0093*)	  and	  a	  Dunnett’s	  test	  revealed	  that	  all	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  (p-­‐value	  =	  0.0363*,	  0.0056*	  and	  0.0263*	  for	  low,	  medium	  and	  high	  treatment	  groups	  respectively).	  R2	  for	  the	  test	  was	  0.580.	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3.4	  Comet	  Assay	  
	  Zero	  time	  samples	  were	  compared	  to	  the	  control	  from	  each	  exposure	  time	  in	  each	  tissue,	  with	  the	  16	  days	  exposure	  group	  split	  in	  two	  depending	  on	  injection.	  	  For	  blood	  the	  Levene’s	  showed	  unequal	  variances	  in	  the	  transformed	  data,	  so	  a	  non-­‐parametric	  approach	  was	  used	  and	  a	  Kruskal-­‐Wallis	  test	  was	  performed	  
Figure	  3.4	  CYP1A	  concentrations	  in	  treated	  groups	  for	  all	  exposure	  times	  (2,	  
8	  and	  16	  days).	  Results	  for	  16	  days	  of	  exposure	  depicted	  with	  PBS	  injected	  
sample	  group.	  Graph	  shows	  medians,	  quartiles,	  minimum	  and	  maximum.	  
Asterisks	  indicate	  treatment	  groups	  with	  significant	  (	  <	  0.0500)	  p-­‐values.	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(Prob	  >	  ChiSq	  =	  0.0164*).	  The	  control	  groups	  for	  8	  days	  (mean-­‐mean0/std0	  =	  	  -­‐1.063),	  16	  days	  with	  LPS	  injection	  (mean-­‐mean0/std0	  =	  -­‐1.669),	  and	  16	  days	  with	  PBS	  injection	  (mean-­‐mean0/std0	  =	  -­‐1.002)	  were	  significantly	  different	  from	  the	  zero	  samples	  (mean-­‐mean0/std0	  =	  0.446),	  whereas	  the	  control	  group	  for	  2	  days	  were	  not	  (mean-­‐mean0/std0	  =	  3.085).	  For	  kidney,	  the	  Levene’s	  test	  also	  showed	  unequal	  variances,	  so	  a	  Kruskal-­‐Wallis	  test	  was	  utilized	  again	  for	  this	  data.	  The	  test	  statistics	  showed	  that	  there	  were	  no	  significant	  differences	  between	  the	  groups	  (Prob	  >	  ChiSq	  =	  0.9611).	  	  	  	  	   	  	  	   	  
Figure	  3.5	  DNA	  damage	  in	  control	  groups	  compared	  to	  the	  zero-­‐
group	  for	  blood	  (A)	  and	  kidney	  (B);	  medians,	  quartiles,	  minimum	  
and	  maximum.	  Asterisks	  indicate	  control	  groups	  that	  are	  
significantly	  (p-­‐value	  <	  0.0500)	  different	  from	  the	  zero	  samples	  
group.	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Furthermore,	  there	  were	  no	  significant	  differences	  between	  treatment	  groups	  and	  the	  control	  at	  any	  exposure	  times	  in	  neither	  the	  data	  from	  obtained	  from	  blood	  samples,	  nor	  in	  the	  data	  obtained	  from	  kidney	  samples.	  	  	  	  
	  	  	  
	   	  
Figure	  3.6	  DNA	  Damage	  in	  blood:	  Every	  treatment	  groups	  for	  all	  exposure	  
times.	  Graph	  shows	  medians,	  quartiles,	  minimum	  and	  maximum.	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Figure	  3.7	  DNA	  Damage	  in	  kidney:	  Every	  treatment	  groups	  for	  all	  exposure	  
times	  (2,	  8	  and	  16	  days	  with	  LPS	  and	  with	  PBS).	  Graph	  shows	  medians,	  
quartiles,	  minimum	  and	  maximum.	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3.5	  Respiratory	  Burst	  	  
	  Due	  to	  lost	  replicates,	  the	  data	  from	  8	  days	  of	  exposure	  unfortunately	  had	  to	  be	  excluded	  from	  the	  analysis.	  Zero	  samples	  were	  first	  analysed	  with	  Levene’s	  test,	  which	  showed	  equal	  variance	  in	  the	  data.	  A	  one-­‐way	  ANOVA	  was	  then	  carried	  out	  to	  assess	  the	  effect	  of	  the	  stimulant	  factor	  (with	  PMA/without	  PMA).	  This	  showed	  that	  there	  was	  no	  significant	  effect	  of	  the	  stimulant	  (Prob	  >	  F	  =	  0.9359	  and	  R2	  =	  0.000478)	  on	  the	  zero	  samples.	  	  Stimulated	  and	  non-­‐stimulated	  control	  groups	  for	  2	  and	  16	  (with	  PBS	  and	  LPS)	  were	  compared	  to	  their	  respective	  zero	  sample	  group.	  As	  Levene’s	  test	  showed	  equal	  variances	  in	  the	  data	  for	  both	  stimulated	  and	  non-­‐stimulated	  cells.	  A	  one-­‐way	  ANOVA	  was	  run	  on	  each	  group.	  There	  were	  no	  significant	  differences	  between	  neither	  of	  the	  control	  groups	  and	  the	  zero	  samples	  (p-­‐value	  =	  0.3441	  for	  PMA	  stimulated	  and	  0.5787	  for	  non-­‐stimulated).	  	  	  For	  the	  data	  from	  2	  days	  of	  exposure,	  a	  2-­‐way	  ANOVA	  was	  done,	  which	  showed	  a	  significant	  effect	  of	  the	  stimulant	  (Prob	  >	  F	  =	  0.0277)	  alone,	  but	  no	  significant	  effect	  from	  treatment	  (Prob	  >	  F	  =	  0.0954)	  or	  from	  stimulant	  and	  treatment	  combined	  (Prob	  >	  F	  =	  0.5755).	  R2	  for	  the	  test	  was	  0.369.	  For	  the	  data	  from	  16	  days	  of	  exposure	  with	  injection	  of	  LPS,	  a	  2-­‐way	  ANOVA	  was	  done.	  There	  was	  no	  significance	  of	  stimulant	  (Prob	  >	  F	  =	  0.3137),	  treatment	  (Prob	  >	  F	  =	  0.8918)	  or	  stimulant	  and	  treatment	  combined	  (Prob	  >	  F	  =	  0.9576).	  R2	  for	  the	  test	  was	  0.074.	  For	  the	  data	  from	  16	  days	  of	  exposure	  with	  injection	  of	  PBS,	  a	  2-­‐way	  ANOVA	  was	  done.	  There	  was	  no	  significance	  of	  stimulant	  (Prob	  >	  F	  =	  0.6420),	  treatment	  (Prob	  >	  F	  =	  0.2083)	  or	  stimulant	  and	  treatment	  combined	  (Prob	  >	  F	  =	  0.9502).	  R2	  for	  the	  test	  was	  0.172059.	  A	  2-­‐way	  ANOVA	  was	  also	  used	  to	  assess	  if	  the	  injection	  of	  LPS	  and	  PBS	  had	  any	  effect.	  The	  analyses	  showed	  that	  there	  were	  no	  significant	  effects	  on	  H2O2	  production	  by	  neither	  LPS	  nor	  PBS	  injection.	  (p-­‐value	  =	  0.9535	  for	  PMA	  stimulated	  replicates	  and	  p-­‐value	  =	  0.8701	  for	  non-­‐stimulated	  replicates).	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Figure	  3.8	  H2O2	  production	  in	  both	  PMA	  stimulated	  and	  non-­‐stimulated	  groups	  in	  zero	  
samples	  and	  for	  all	  treatments	  after	  2	  and	  16	  days	  exposure.	  Graph	  shows	  medians,	  
quartiles,	  minimum	  and	  maximum.	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3.6	  PAH	  Metabolites	  in	  Bile	  
3.6.1	  OH-­‐Pyrene	  	  First,	  a	  comparison	  between	  the	  control	  group	  from	  each	  exposure	  time,	  and	  the	  zero	  samples	  group	  was	  done.	  A	  Levene’s	  test	  showed	  that	  there	  were	  equal	  variances	  in	  the	  data,	  so	  a	  one-­‐way	  ANOVA	  was	  done.	  The	  test	  statistic	  was	  not	  significant	  (p-­‐value	  =	  0.1867)	  indicating	  that	  none	  of	  the	  control	  groups	  were	  significantly	  different	  from	  the	  zero	  samples	  group.	  	  For	  the	  data	  from	  2	  days	  of	  exposure	  a	  Levene’s	  test	  showed	  that	  variance	  was	  unequal.	  As	  the	  data	  had	  already	  been	  transformed,	  a	  non-­‐parametric	  approach	  was	  used	  to	  analyse	  the	  data	  and	  a	  Kruskal-­‐Wallis	  test	  was	  done.	  Χ2	  was	  not	  significant	  (p-­‐value	  =	  0.4559)	  indicating	  that	  there	  was	  no	  effect	  of	  the	  treatments.	   The	  data	  for	  8	  days	  of	  exposure	  showed	  equal	  variances	  with	  a	  Levene’s	  test	  and	  a	  one-­‐way	  ANOVA	  was	  done.	  This	  showed	  that	  there	  was	  a	  significant	  difference	  in	  the	  treatment	  groups	  relative	  to	  the	  control	  (p-­‐value	  =	  0.0323*).	  A	  Dunnet’s	  test	  showed	  that	  the	  high	  treatment	  group	  was	  significantly	  different	  from	  the	  control	  (p-­‐value	  =	  0.0185).	  R2	  for	  the	  test	  was	  0.40.	  For	  the	  data	  from	  16	  days	  of	  exposure,	  a	  Levene’s	  test	  showed	  that	  the	  variance	  was	  equal,	  and	  a	  one-­‐way	  ANOVA	  was	  done.	  This	  showed	  that	  there	  were	  significant	  differences	  in	  the	  treatment	  groups	  (p-­‐value	  =	  0.0069*).	  A	  Dunnet’s	  test	  showed	  that	  all	  of	  the	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  (p-­‐values	  0.0134*,	  0.0083*	  and	  0.0211*	  for	  the	  low,	  medium	  and	  high	  treatment	  groups	  respectively).	  R2	  for	  the	  test	  was	  0.654319.	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Figure	  3.9	  PAH	  metabolites	  (pyrene):	  Every	  treatment	  groups	  for	  all	  exposure	  times	  
(2,	  8	  and	  16	  days).	  Results	  for	  16	  days	  of	  exposure	  depicted	  with	  PBS	  injected	  sample	  
group.	  Graph	  shows	  medians,	  quartiles,	  minimum	  and	  maximum.	  Asterisks	  indicate	  
treatment	  groups	  with	  significant	  (	  <	  0.0500)	  p-­‐values.	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3.6.2	  OH-­‐Phenatrene	  	  A	  comparison	  between	  the	  control	  group	  from	  each	  exposure	  time,	  and	  the	  zero	  samples	  group	  was	  done.	  A	  Levene’s	  test	  showed	  that	  there	  were	  equal	  variances	  in	  the	  data,	  so	  a	  one-­‐way	  ANOVA	  was	  performed.	  The	  test	  statistic	  was	  not	  significant	  (p-­‐value	  =	  0.1684)	  indicating	  that	  none	  of	  the	  control	  groups	  were	  significantly	  different	  from	  the	  zero	  samples	  group.	  For	  the	  data	  from	  2	  days	  of	  exposure	  a	  Levene’s	  test	  showed	  that	  variance	  in	  the	  data	  was	  equal.	  A	  one-­‐way	  ANOVA	  was	  done.	  This	  showed	  that	  there	  was	  a	  significant	  difference	  in	  the	  treated	  groups	  (p-­‐value	  =	  <.0001).	  	  A	  Dunnet’s	  test	  showed	  that	  all	  of	  the	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  (p-­‐values	  0.0002,	  <0.0001	  and	  <0.0001	  for	  the	  low,	  medium	  and	  high	  treatment	  groups	  respectively).	  R2	  for	  the	  test	  was	  0.842.	  For	  the	  data	  from	  8	  days	  of	  exposure,	  a	  Levene’s	  test	  showed	  that	  the	  data	  had	  equal	  variances	  and	  a	  one-­‐way	  ANOVA	  was	  done.	  This	  showed	  that	  there	  was	  a	  significant	  difference	  in	  the	  treated	  groups	  (p-­‐value	  =	  <.0001*).	  	  A	  Dunnet’s	  test	  showed	  that	  all	  of	  the	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  (p-­‐values	  were	  <0.0001	  for	  both	  the	  low,	  medium	  and	  high	  treatment	  groups).	  R2	  for	  the	  test	  was	  0.826.	  For	  the	  data	  from	  16	  days	  of	  exposure,	  a	  Levene’s	  test	  showed	  that	  there	  were	  equal	  variances	  in	  the	  data	  and	  a	  one-­‐way	  ANOVA	  was	  done.	  This	  showed	  that	  there	  was	  a	  significant	  difference	  in	  the	  treated	  groups	  (p-­‐value	  =	  <.0001*).	  	  A	  Dunnet’s	  test	  showed	  that	  all	  of	  the	  treatment	  groups	  were	  significantly	  different	  from	  the	  control	  (p-­‐values	  were	  <0.0001*	  for	  both	  the	  low,	  medium	  and	  high	  treatment	  groups).	  R2	  for	  the	  test	  was	  0.89337.	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Figure	  3.10	  PAH	  metabolites	  (phrnatrene):	  Every	  treatment	  groups	  for	  all	  exposure	  
times	  (2,	  8	  and	  16	  days).	  Results	  for	  16	  days	  of	  exposure	  depicted	  with	  PBS	  injected	  
sample	  group.	  Graph	  shows	  medians,	  quartiles,	  minimum	  and	  maximum.	  Asterisks	  
indicate	  treatment	  groups	  with	  significant	  (	  <	  0.0500)	  p-­‐values.	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3.7	  Correlations	  The	  correlations	  analysis	  was	  done	  using	  a	  multivariate	  method	  and	  testing	  with	  Spearman’s	  p	  test.	  	  	  
Table	  3.1	  Correlation	  data.	  Only	  correlated	  variables	  are	  shown.	  Asterisks	  indicate	  significant	  (	  <	  0.05)	  p-­‐values.	  	  
2	  days	  of	  exposure	  
Variable	   By	  variable	   Speaman’s	  p	   p-­‐value	  OH-­‐Phenatrene	   OH-­‐Pyrene	   0.6029	   0.01*	  Respiratory	  burst	  NO	  PMA	   Respiratory	  burst	  PMA	   0.5676	   0.02*	  
8	  days	  of	  exposure	  
Variable	   By	  variable	   Speaman’s	  p	   p-­‐value	  OH-­‐Phenatrene	   OH-­‐Pyrene	   0.8312	   <.0001*	  ELISA	  mean	  OD	   OH-­‐Pyrene	   0.4390	   0.05*	  ELISA	  mean	  OD	   OH-­‐Phenatrene	   0.6675	   0.0009*	  EROD	  pmol/min/mg	  protein	   OH-­‐Phenatrene	   0.5013	   0.02*	  EROD	  pmol/min/mg	  protein	   ELISA	  mean	  OD	   0.8078	   <.0001*	  Respiratory	  burst	  PMA	   ELISA	  mean	  OD	   -­‐0.5676	   0.02*	  Respiratory	  burst	  PMA	   Weight	   0.6194	   0.01*	  Respiratory	  burst	  PMA	   Comet	  median	  TI	  blood	   0.5147	   0.04*	  Comet	  median	  TI	  kidney	   Comet	  median	  TI	  blood	   0.7391	   <.0001*	  Comet	  median	  TI	  kidney	   Respiratory	  burst	  PMA	   0.6412	   0.007*	  Respiratory	  burst	  NO	  PMA	   ELISA	  mean	  OD	   -­‐0.6118	   0.01*	  Respiratory	  burst	  NO	  PMA	   Weight	   0.6785	   0.004*	  Respiratory	  burst	  NO	  PMA	   Length	   0.6667	   0.005*	  Respiratory	  burst	  NO	  PMA	   Respiratory	  burst	  PMA	   0.7588	   0.0007*	  
16	  days	  of	  exposure	  with	  LPS	  injection	  
Variable	   By	  variable	   Speaman’s	  p	   p-­‐value	  OH-­‐Phenatrene	   OH-­‐Pyrene	   0.7500	   0.0008*	  EROD	  pmol/min/mg	  protein	   OH-­‐Phenatrene	   0.9375	   <.0001*	  Respiratory	  burst	  NO	  PMA	   OH-­‐Pyrene	   0.6118	   0.01*	  Respiratory	  burst	  NO	  PMA	   Respiratory	  burst	  PMA	   0.8971	   <.0001*	  
16	  days	  of	  exposure	  with	  PBS	  injection	  
Variable	   By	  variable	   Speaman’s	  p	   p-­‐value	  OH-­‐Phenatrene	   OH-­‐Pyrene	   0.8857	   <.0001*	  ELISA	  mean	  OD	   OH-­‐Pyrene	   0.5214	   0.05*	  ELISA	  mean	  OD	   OH-­‐Phenatrene	   0.6643	   0.007*	  EROD	  pmol/min/mg	  protein	   ELISA	  mean	  OD	   0.5539	   0.02*	  Respiratory	  burst	  NO	  PMA	   Respiratory	  burst	  PMA	   0.8848	   <.0001*	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4	  Discussion	  
4.1	  PAH	  metabolites	  in	  bile	  
	  Fish	  may	  be	  exposed	  to	  PAHs	  via	  the	  gills	  or	  through	  their	  diet	  (Grung	  et	  al.	  2009).	  PAH	  metabolites	  in	  bile	  are	  the	  results	  of	  compounds	  that	  enter	  and	  interact	  with	  the	  biological	  system	  where	  it	  induces	  various	  reactions	  associated	  with	  biotransformation.	  The	  presence	  of	  elevated	  levels	  of	  metabolites	  shows	  that	  the	  organism	  has	  been	  exposed	  to	  PAHs	  through	  its	  environment	  (Van	  der	  Oost	  et	  al.	  2003,	  Grung	  et	  al.	  2009,	  Beyer	  et	  al.	  2010).	  The	  data	  analysis	  focused	  on	  the	  metabolites	  1-­‐OH-­‐phenantrene	  and	  1-­‐OH-­‐pyrene.	  Phenanthrene	  consists	  of	  three	  aromatic	  rings	  while	  pyrene	  consists	  of	  four	  (Hylland	  2006).	  Three,	  four	  and	  five-­‐ring	  compounds	  are	  most	  abundant	  in	  the	  distribution	  of	  PAHs	  (Page	  et	  al.	  1999),	  and	  this	  should	  support	  this	  analysis	  main	  focus	  on	  phenanthrene	  and	  pyrene.	  	  	  The	  results	  related	  to	  phenatrene	  accumulation	  were	  very	  defined	  and	  the	  results	  illustrate	  a	  clear	  correlation	  between	  treatment	  and	  elevated	  concentrations	  of	  phenatrene	  in	  the	  bile.	  After	  8	  days	  of	  exposure	  there	  was	  a	  visible	  dose-­‐response	  pattern	  with	  median	  metabolite	  amount	  increasing	  with	  treatment.	  	  For	  2	  and	  16	  days	  of	  exposure	  the	  median	  for	  the	  High	  treatment	  was	  slightly	  lower,	  but	  close	  to	  that	  of	  the	  medium	  treatment,	  which	  could	  indicate	  that	  the	  initial	  conditioning	  and	  response	  to	  the	  oil	  exposure	  peaks	  at	  the	  medium	  concentration,	  perhaps	  due	  to	  higher	  concentrations	  being	  a	  redundant	  factor	  for	  making	  the	  fish	  maximize	  their	  biotransformation	  responses.	  	  The	  results	  for	  pyrene	  showed	  that	  after	  2	  days	  of	  exposure	  there	  were	  no	  significant	  differences	  in	  the	  treated	  groups	  and	  after	  8	  days	  of	  exposure,	  only	  the	  High	  treatment	  group	  was	  significantly	  different.	  The	  data	  for	  16	  days	  of	  exposure	  showed	  the	  same	  tendency	  as	  the	  phenatrene	  data	  for	  2	  and	  16	  days	  of	  exposure	  with	  a	  higher	  median	  for	  the	  medium	  treatment.	  	  The	  elevated	  amount	  of	  phenatrene	  compared	  to	  pyrene,	  is	  most	  likely	  due	  to	  the	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PAH	  content	  in	  the	  WAF	  of	  oil	  containing	  higher	  amounts	  of	  two-­‐	  and	  three-­‐ring	  components	  and	  lower	  levels	  of	  heavier	  PAHs	  such	  as	  pyrene	  (Hylland	  2006).	  	  This	  temporal	  tendency	  in	  the	  results	  seems	  to	  oppose	  previously	  observed	  temporal	  patterns	  in	  fluorescence	  (Aas	  et	  al.	  2000),	  where	  the	  PAH	  levels	  increase	  rapidly	  in	  the	  beginning	  of	  the	  exposure	  period	  and	  more	  steadily	  for	  the	  rest	  of	  the	  period.	  In	  most	  of	  the	  studies	  where	  this	  has	  been	  observed,	  it	  has	  been	  with	  caged	  fish	  in	  suspected	  polluted	  areas.	  Such	  a	  pattern	  would	  make	  sense	  in	  an	  uncontrolled	  exposure	  environment	  such	  as	  in	  an	  oil	  spill	  area,	  where	  the	  amount	  of	  PAHs	  available	  for	  accumulation	  will	  decrease	  over	  time.	  A	  constant	  input-­‐flow	  was	  maintained	  in	  this	  experiment,	  so	  the	  PAHs	  would	  not	  decrease	  over	  time.	  This	  seems	  to	  be	  in	  accordance	  with	  the	  observed	  pattern	  where	  there	  were	  still	  high	  concentrations	  of	  metabolites	  after	  the	  longest	  exposure	  period.	  
	  
4.2	  Hepatic	  ethoxyresorufin	  O-­‐deethylase	  (EROD)	  Activity	  
	  The	  correlation	  analysis	  indicated	  that	  EROD	  activity	  levels	  were	  correlated	  with	  PAH	  metabolite	  levels,	  more	  specifically	  OH-­‐phenatrene	  concentrations	  for	  both	  8	  and	  16	  days	  of	  exposure.	  EROD	  activity	  is	  a	  pathway	  for	  the	  formation	  of	  PAH	  metabolites	  (Aas	  et	  al.	  2001),	  which	  gives	  further	  support	  to	  the	  correlation	  observed.	  Other	  studies,	  such	  as	  that	  carried	  out	  by	  McDonald	  et	  al.	  (1995),	  have	  previously	  documented	  a	  connection	  between	  phenatrene	  metabolites	  and	  elevated	  EROD	  activity	  levels.	  Additionally,	  the	  high	  fat	  percentage	  in	  cod	  liver	  (40-­‐70%)	  makes	  the	  organ	  especially	  susceptible	  to	  accumulation	  of	  lipophilic	  contaminants	  (Husøy	  et	  al.	  1996).	  It	  has	  been	  suggested	  that	  this	  may	  contribute	  to	  an	  inhibition	  of	  EROD	  induction	  (Bernhoft	  et	  al.	  1994)	  and	  may	  help	  explain	  why	  CYP1A	  induction	  has	  been	  unevenly	  distributed	  in	  some	  studies	  (Husøy	  et	  al.	  1994).	  The	  pattern	  observed	  in	  EROD	  activity	  from	  this	  study	  indicated	  that	  mean	  EROD	  activity	  was	  highest	  in	  cod	  from	  the	  low	  treatment	  after	  2	  days	  of	  exposure	  and	  then	  decreased	  with	  treatment.	  For	  8	  days	  of	  exposure	  the	  median	  EROD	  activity	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did	  not	  seem	  to	  differ	  very	  much	  between	  the	  treatments,	  and	  at	  16	  days	  of	  exposure	  injected	  with	  both	  LPS	  and	  PBS,	  the	  mean	  EROD	  activity	  peaked	  at	  the	  medium	  treatment,	  while	  the	  low	  and	  high	  treatment	  EROD	  activity	  levels	  remained	  lower.	  	  This	  pattern	  shows	  some	  similarities	  with	  results	  obtained	  in	  studies	  with	  polar	  cod	  (Boreogadus	  saida)	  that	  used	  related	  oil	  concentrations	  (Nahrgang	  et	  al.	  2010,	  Nahrgang	  et	  al.	  2010).	  The	  oil	  treatments	  described	  in	  these	  studies	  as	  medium	  and	  high	  treatment	  correspond	  to	  the	  concentrations	  used	  in	  the	  present	  study	  for	  low	  and	  medium	  treatments.	  The	  pattern	  they	  observed	  after	  0+	  days	  corresponds	  to	  the	  pattern	  seen	  in	  this	  study	  after	  2	  days	  of	  exposure,	  while	  the	  pattern	  after	  2	  weeks	  in	  the	  two	  studies	  corresponds	  to	  8	  and	  16	  days	  of	  exposure	  in	  this	  study	  (although	  not	  as	  clearly	  visible	  after	  8	  days).	  Therefore,	  there	  seems	  to	  be	  compliance	  with	  previously	  observed	  patterns	  in	  EROD	  activity.	  	  The	  shift	  in	  the	  pattern	  between	  the	  early	  stages	  of	  the	  experiment	  and	  the	  later	  stages	  could	  possibly	  be	  connected	  to	  elevated	  stress	  factors	  during	  the	  first	  days	  of	  the	  experiment,	  but	  as	  there	  is	  no	  data	  to	  support	  this	  assumption	  it	  will	  not	  be	  further	  discussed	  here.	  It	  is	  also	  possible	  that	  the	  change	  in	  pattern	  could	  have	  been	  related	  to	  the	  injection	  of	  a	  pathogen	  challenge	  thirteen	  days	  into	  the	  experiment,	  as	  a	  change	  in	  hepatic	  EROD	  activity	  has	  previously	  been	  observed	  in	  carp	  (Cyprinus	  carpio)	  that	  had	  been	  intraperitoneally	  injected	  with	  LPS.	  In	  carp,	  the	  injection	  caused	  a	  down	  regulation	  of	  CYP1A	  in	  liver	  and	  spleen,	  but	  at	  the	  same	  time	  an	  increase	  in	  hepatic	  EROD	  activity	  levels	  (Marionnet	  et	  al.	  1998).	  Although	  there	  are	  species	  differences	  to	  consider,	  it	  has	  been	  established	  that	  LPS	  triggers	  biotransformation	  processes	  and	  may	  affect	  induction	  of	  biotransformation	  enzymes	  (Marionnet	  et	  al.	  1998).	  The	  general	  trend	  in	  LPS	  and	  PBS	  injected	  fish	  in	  this	  study	  was	  similar	  and	  statistically,	  there	  were	  no	  significant	  differences	  between	  each	  treatment	  group	  when	  LPS	  and	  PBS	  injected	  groups	  were	  compared.	  Although	  the	  high	  treatment	  group	  among	  the	  LPS	  injected	  fish	  showed	  to	  be	  significantly	  different	  from	  the	  control,	  the	  same	  treatment	  group	  among	  the	  PBS	  injected	  fish	  was	  not	  significant,	  indicating	  that	  the	  LPS	  injection	  may	  have	  induced	  higher	  EROD	  activity	  in	  the	  fish	  that	  were	  also	  subjected	  to	  elevated	  stress	  from	  the	  highest	  exposure	  to	  oil.	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4.3	  CYP1A	  concentrations	  	  There	  was	  a	  clear	  correlation	  between	  EROD	  activity	  and	  CYP1A	  levels	  after	  8	  days	  of	  exposure,	  in	  addition	  to	  a	  correlation	  between	  OH-­‐phenatrene,	  OH-­‐pyrene	  and	  CYP1A	  levels.	  The	  same	  correlation	  was	  present	  after	  16	  days	  of	  exposure.	  CYP1A	  plays	  a	  major	  role	  in	  the	  biotransformation	  of	  PAHs	  (Stegeman	  et	  al.	  1991)	  so	  the	  correlation	  seems	  to	  support	  potential	  effects	  from	  PAHs	  in	  the	  oil.	  Previous	  studies	  have	  already	  established	  a	  correlation	  between	  exposure	  to	  PAHs	  and	  elevated	  EROD	  activity	  and	  CYP1A	  levels	  measured	  by	  the	  ELISA	  assay,	  specifically	  in	  Atlantic	  cod	  (Gadus	  morhua)	  and	  European	  flounder	  (Platichthys	  j’	  ksus)	  that	  had	  been	  exposed	  to	  (b-­‐naphthoflavone)	  (Husøy	  et	  al.	  1996)	  and	  in	  Atlantic	  cod	  and	  corkwing	  wrasse	  (Symphodus	  melops)	  exposed	  to	  naphthalene,	  pyrene	  and	  benzo[a]pyrene	  (Aas	  et	  al.	  2001).	  The	  pattern	  in	  the	  data	  did	  not	  exactly	  resemble	  a	  dose-­‐response	  relationship.	  In	  a	  previous	  study	  where	  cod	  was	  exposed	  to	  other	  contaminants	  (PCB-­‐105),	  it	  was	  suspected	  that	  unevenly	  distributed	  data	  could	  be	  connected	  to	  early	  samplings,	  resulting	  in	  contaminant	  levels	  not	  being	  substantial	  enough	  to	  induce	  elevated	  EROD	  and	  CYP1A	  levels	  (Bernhoft	  et	  al.	  1994).	  	  The	  flow	  used	  in	  this	  system	  was	  stable,	  but	  accumulation	  extensive	  enough	  to	  cause	  a	  response	  could	  be	  somehow	  delayed	  in	  this	  experiment	  as	  well.	  However,	  the	  results	  do	  not	  indicate	  that	  there	  was	  a	  tendency	  to	  higher	  mean	  OD	  in	  the	  samples	  exposed	  for	  the	  longest	  time	  period	  (16	  days).	  In	  contrast,	  the	  data	  for	  8	  days	  of	  exposure	  seems	  generally	  slightly	  higher	  in	  at	  least	  the	  medium	  and	  high	  treatment	  groups,	  so	  delayed	  uptake	  as	  an	  explanation	  to	  the	  non-­‐dose	  dependent	  pattern	  observed	  remains	  questionable.	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4.4	  DNA	  strand	  breaks	  
	  This	  study	  was	  looking	  into	  whether	  or	  not	  there	  would	  be	  significant	  DNA	  damage	  as	  a	  result	  of	  the	  oil	  exposure.	  The	  study	  showed	  that	  there	  were	  no	  significant	  results	  for	  any	  treatment	  groups	  after	  the	  different	  exposure	  periods.	  The	  data	  was	  characterized	  by	  high	  variance,	  and	  when	  analysing	  the	  variances,	  R2	  for	  most	  of	  the	  exposure	  times	  indicated	  that	  the	  model	  was	  only	  to	  a	  very	  low	  degree	  able	  to	  explain	  the	  variances	  in	  the	  data.	  	  A	  relationship	  between	  exposure	  to	  PAHs	  and	  DNA	  damage	  has	  previously	  been	  described	  in	  a	  study	  using	  polar	  cod	  (Boreogadus	  saida).	  DNA	  damage	  measured	  using	  the	  comet	  assay	  was	  correlated	  with	  PAH	  metabolites;	  pyrene	  and	  benzo(a)pyrene	  (Nahrgang	  et	  al.	  2010).	  There	  were	  no	  correlations	  between	  DNA	  damage	  and	  PAH	  metabolites	  in	  this	  study	  and	  no	  apparent	  effect	  from	  the	  oil	  treatment.	  	  However	  there	  was	  a	  strong	  correlation	  observed	  between	  DNA	  damage	  in	  blood	  and	  DNA	  damage	  in	  kidney,	  as	  well	  as	  a	  relationship	  between	  DNA	  damage	  in	  both	  blood	  and	  kidney	  and	  the	  PMA	  stimulated	  response	  in	  the	  respiratory	  burst	  assay.	  The	  head	  kidney	  is	  the	  organ	  where	  leukocytes	  are	  matured	  and	  then	  distributed	  to	  the	  rest	  of	  the	  system,	  so	  an	  increase	  in	  DNA	  damaged	  leukocytes	  in	  this	  organ	  could	  account	  for	  the	  distribution	  of	  damaged	  cells	  to	  the	  bloodstream.	  Damage	  to	  the	  DNA	  strand	  may	  be	  caused	  by	  toxic	  metabolites	  (Gravato	  et	  al.	  2003)	  or	  may	  occur	  after	  increased	  ROS	  production	  (Regoli	  et	  al.	  2003).	  PAHs	  are	  also	  known	  to	  induce	  the	  production	  of	  ROS	  (Nahrgang	  et	  al.	  2010)which	  may	  explain	  the	  observed	  correlation	  between	  DNA	  damage	  in	  blood	  and	  kidney	  and	  the	  response	  on	  the	  respiratory	  burst	  assay.	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4.5	  Effects	  on	  immune	  responses	  
	  Respiratory	  burst	  plays	  an	  important	  role	  in	  the	  immune	  system	  because	  it	  is	  a	  reaction	  that	  occurs	  in	  phagocytes	  and	  is	  involved	  in	  the	  degradation	  of	  internalized	  particles	  and	  bacteria	  (Nikoskelainen	  et	  al.	  2006).	  The	  degradation	  is	  connected	  to	  catalase	  enzymes	  which	  catalyse	  the	  breakdown	  of	  reactive	  oxygen	  species	  to	  water	  and	  oxygen	  and,	  therefore,	  plays	  an	  important	  part	  in	  protecting	  the	  cell	  from	  oxidative	  stress	  and	  damage	  (Chelikani	  et	  al.	  2004).	  The	  cells	  in	  this	  study	  were	  activated	  with	  PMA,	  and	  the	  production	  of	  H2O2	  was	  measured	  to	  assess	  the	  individual	  ability	  to	  induce	  an	  immune	  response.	  The	  data	  showed	  a	  significant	  effect	  of	  treatment	  only	  for	  2	  days	  of	  exposure.	  Although	  the	  exposure	  periods	  could	  not	  be	  statistically	  compared,	  the	  data	  pattern	  suggest	  that	  median	  H2O2	  production	  is	  higher	  after	  16	  days	  of	  exposure.	  Furthermore,	  as	  the	  statistic	  analyses	  also	  verified,	  the	  pattern	  shows	  that	  there	  is	  no	  obvious	  effect	  of	  PMA	  stimulation	  (median	  H2O2	  production	  is	  very	  close	  for	  stimulated	  and	  non-­‐stimulated	  replicates	  in	  all	  treatment	  and	  exposure	  groups).	  The	  comparison	  between	  the	  LPS	  and	  the	  PBS	  injected	  groups	  for	  16	  days	  of	  exposure	  further	  showed	  that	  the	  injection	  had	  no	  effect	  on	  respiratory	  burst.	  These	  results	  contradict	  a	  previous	  long-­‐term	  study	  by	  Hamoutene	  et	  al.	  (2011)	  where	  cod	  were	  exposed	  to	  PAHs	  through	  produced	  water,	  and	  where	  the	  fish	  were	  also	  injected	  with	  either	  an	  LPS	  or	  PBS.	  The	  study	  examined	  both	  respiratory	  burst	  of	  whole	  blood,	  which	  was	  not	  affected,	  and	  respiratory	  burst	  in	  head	  kidney,	  which	  was	  significantly	  decreased	  after	  the	  fish	  had	  been	  injected	  with	  LPS.	  The	  decrease	  was	  strongest	  in	  fish	  that	  had	  been	  exposed	  to	  the	  highest	  concentrations.	  Inhibition	  of	  the	  immune	  responses	  was	  argued	  to	  be	  a	  result	  of	  the	  vast	  effects	  of	  LPS	  on	  the	  natural	  immune	  cells’	  reactions.	  It	  is	  contradictory	  because,	  in	  the	  present	  study,	  the	  pattern	  shows	  that	  the	  lower	  and	  medium	  treatments	  generally	  have	  more	  elevated	  medians	  than	  the	  higher	  ones.	  It	  is	  however,	  likely	  that	  the	  acute	  and	  longer-­‐term	  effects	  could	  be	  very	  different.	  A	  study	  on	  stress	  effects	  in	  rainbow	  trout	  (Oncorhynchus	  mykiss)	  argued	  that	  acute	  stress	  would	  act	  as	  a	  stimulant	  on	  the	  innate	  immune	  system	  rather	  than	  inhibiting	  it,	  in	  an	  attempt	  to	  protect	  the	  fish	  (Demers	  et	  al.	  1997).	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Moreover,	  it	  is	  possible	  that	  the	  immune	  system	  would	  adapt	  to	  the	  chronic	  conditions	  after	  a	  period	  of	  time,	  which	  could	  explain	  the	  significant	  treatment	  effect	  after	  2	  days	  but	  not	  after	  16	  days.	  	  The	  correlation	  analysis	  showed	  that	  the	  size	  of	  the	  fish	  was	  correlated	  with	  the	  immune	  response.	  The	  fish	  used	  were	  all	  juveniles	  with	  the	  same	  age,	  but	  there	  were	  some	  weight	  and	  length	  variances.	  Magnadóttir	  et	  al.	  (1999)	  have	  previously	  shown	  that	  humoral	  immune	  parameters	  in	  cod	  are	  influenced	  by	  its	  size,	  and	  it	  has	  been	  argued	  that	  this	  may	  be	  due	  to	  a	  primitive	  regulatory	  system	  (Magnadóttir	  et	  al.	  1999).	  	  The	  absence	  of	  significant	  immune	  responses	  related	  to	  oil	  treatments	  and	  LPS/PBS	  injection	  does	  not	  seem	  logical;	  however,	  it	  has	  previously	  been	  established	  that	  inducing	  immune	  responses	  in	  cod	  is	  challenging	  (Espelid	  et	  al.	  1991,	  Schrøder	  et	  al.	  1992).	  In	  that	  sense,	  the	  results	  of	  the	  present	  study	  are	  consistent	  with	  existing	  literature	  and	  not	  entirely	  anomalous.	  	  	  
4.6	  Interspecies	  Comparisons	  	  There	  were	  quite	  substantial	  species	  differences	  when	  it	  came	  to	  the	  biomarkers	  of	  exposure.	  Although	  turbot	  showed	  significant	  differences	  on	  EROD	  activity	  at	  all	  treatments,	  this	  was	  only	  the	  case	  for	  2	  days	  of	  exposure.	  There	  were	  no	  significant	  results	  for	  CYP1A	  levels	  at	  any	  times	  of	  exposure	  either.	  Results	  for	  PAH	  metabolites	  in	  bile	  were	  more	  substantial;	  for	  phenatrene	  turbot	  had	  significant	  differences	  relative	  to	  the	  control	  in	  all	  treatment	  groups	  at	  all	  exposure	  times,	  and	  for	  pyrene	  the	  medium	  treatment	  was	  significantly	  different	  for	  the	  medium	  treatment	  at	  8	  and	  16	  days	  of	  exposure.	  Accumulated	  PAHs	  in	  the	  bile	  in	  turbot	  indicates	  that	  the	  oil	  was	  in	  fact	  bioavailable	  and	  accumulating	  in	  turbot	  as	  well.	  It	  should	  be	  noted	  that	  hardly	  any	  of	  the	  turbot	  were	  feeding	  during	  the	  experiment.	  Due	  to	  this,	  the	  gall	  bladder	  was	  very	  full,	  and	  the	  absence	  of	  bile	  removal	  from	  the	  gall	  bladder	  during	  the	  entire	  experiment	  could	  possibly	  explain	  a	  higher	  accumulation	  of	  PAHs	  in	  the	  bile.	  The	  presence	  of	  elevated	  PAH	  metabolite	  levels	  in	  both	  species	  indicate	  that	  the	  different	  CYP1A	  levels	  and	  EROD	  activity	  are	  species	  specific.	  	  There	  were	  no	  significant	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differences	  in	  DNA	  damage	  between	  the	  treatment	  groups	  in	  turbot	  either,	  and	  no	  significant	  results	  in	  respiratory	  burst	  related	  to	  the	  oil	  exposure,	  which	  could	  point	  to	  similarities	  in	  the	  way	  the	  immune	  system	  responds	  in	  both	  species,	  or	  it	  could	  be	  due	  to	  methodology.	  	  
4.7	  Conclusions	  	  The	  biomarkers	  of	  exposure	  utilized	  in	  this	  study	  were	  successful	  in	  linking	  exposure	  to	  the	  oil	  treatments	  to	  metabolic	  reactions.	  EROD	  activity	  was	  increased	  and	  there	  was	  a	  clear	  connection	  between	  elevated	  CYP1A	  levels	  in	  treated	  groups	  compared	  to	  the	  control.	  There	  was	  a	  strong	  relationship	  between	  treated	  groups	  and	  elevated	  PAH	  metabolite	  levels	  in	  bile.	  Together,	  these	  biomarkers	  showed	  that	  there	  was	  an	  effect	  of	  the	  oil	  on	  biotransformation	  pathways.	  The	  study	  did	  not	  reveal	  any	  differences	  in	  DNA	  damages	  between	  the	  treated	  groups,	  and	  the	  oil	  exposure	  did	  thus	  not	  appear	  to	  affect	  this	  parameter.	  	  	  Neither	  did	  the	  oil	  seem	  to	  have	  any	  significant	  effect	  on	  the	  immune	  responses,	  as	  there	  were	  no	  treatment	  effects	  on	  respiratory	  burst.	  This	  may	  be	  connected	  to	  the	  fact	  that	  stimulation	  of	  the	  leukocytes	  proved	  ineffective	  in	  generating	  a	  cellular	  response.	  It	  is	  possible	  that	  these	  methods	  need	  further	  study	  and	  optimization	  before	  successful	  results	  may	  be	  developed	  and	  new	  links	  between	  oil	  exposure	  and	  immune	  responses	  established.	  Major	  effects	  of	  the	  injected	  challenge	  could	  not	  be	  conclusively	  determined,	  although	  there	  were	  some	  indications	  that	  some	  of	  the	  biomarkers	  were	  somewhat	  affected.	  It	  is	  possible	  that	  a	  more	  specific	  study	  into	  the	  effects	  of	  other	  immune	  parameters	  would	  yield	  more	  conclusive	  results.	  	  It	  was	  not	  possible	  to	  compare	  exposure	  times	  directly	  due	  to	  the	  experiment	  design,	  although	  the	  trends	  in	  the	  data	  did	  appear	  to	  show	  some	  effects	  related	  to	  exposure	  period.	  For	  EROD	  activity,	  the	  pattern	  did	  not	  show	  differences	  between	  specific	  treatments	  at	  different	  exposure	  periods	  although	  there	  was	  some	  observable	  variation	  in	  mean	  concentration.	  	  CYP1A	  levels	  appeared	  to	  show	  a	  relative	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difference	  for	  each	  treatment	  at	  different	  exposure	  periods,	  especially	  between	  the	  first	  and	  the	  last	  sampling.	  Although	  it	  could	  not	  be	  statistically	  verified,	  it	  could	  indicate	  some	  effect	  of	  exposure	  period.	  PAH	  metabolites	  levels	  in	  bile	  were	  similar	  in	  each	  treatment	  group	  at	  different	  times	  of	  exposure.	  The	  pattern	  in	  amount	  of	  DNA	  damage	  did	  not	  seem	  to	  vary	  in	  relation	  to	  exposure	  period	  either,	  which	  is	  consistent	  with	  the	  finding	  that	  the	  oil	  did	  in	  fact	  not	  affect	  amounts	  of	  DNA	  damage.	  	  The	  immune	  responses	  showed	  a	  trend	  of	  generally	  higher	  mean	  respiratory	  burst	  in	  all	  treatments	  for	  the	  longest	  exposure	  period	  compared	  to	  the	  shortest	  exposure	  period,	  which	  could	  indicate	  that	  longer	  exposure	  would	  be	  more	  likely	  to	  trigger	  an	  immune	  function.	  In	  regards	  to	  the	  injected	  challenge,	  the	  EROD	  activity	  in	  the	  LPS	  injected	  high	  treatment	  group	  was	  significantly	  different	  from	  control,	  but	  not	  significantly	  different	  from	  the	  high	  treatment	  group	  injected	  with	  PBS.	  Furthermore,	  there	  were	  no	  significant	  differences	  in	  immune	  responses	  measured.	  From	  this	  it	  can	  be	  gathered	  that	  injection	  in	  it	  self	  did	  not	  change	  the	  immunocompetence	  in	  this	  study.	  	  	  There	  were	  species	  differences	  in	  EROD	  activity	  and	  quite	  substantial	  differences	  in	  CYP1A	  levels,	  which	  in	  turbot	  did	  not	  seem	  affected	  by	  the	  oil	  treatments	  like	  they	  were	  in	  cod.	  The	  PAH	  metabolites	  in	  bile	  revealed	  that	  both	  species	  had	  bioaccumulated	  high	  amounts	  of	  PAHs,	  so	  the	  differences	  in	  CYP1A	  levels	  and	  EROD	  activity	  appeared	  to	  be	  species	  specific.	  There	  were	  no	  significant	  differences	  in	  DNA	  damage	  between	  the	  treatment	  groups	  in	  turbot	  either,	  and	  no	  significant	  results	  in	  respiratory	  burst	  related	  to	  the	  oil	  exposure.	  This	  could	  point	  to	  similarities	  in	  the	  way	  the	  immune	  system	  responds	  in	  both	  species,	  or	  it	  could	  be	  due	  to	  an	  unknown	  error	  in	  methodology.	  	  	  It	  is	  important	  to	  note	  that	  in	  their	  natural	  habitat,	  organisms	  may	  be	  exposed	  to	  more	  than	  one	  contaminant,	  which	  may	  at	  any	  given	  time	  interact	  with	  and	  change	  the	  single	  effect	  of	  one	  another.	  The	  WAF	  of	  crude	  oil	  contains	  several	  other	  components	  that	  PAHs	  and	  the	  interaction	  between	  contaminants	  is	  an	  important	  factor.	  It	  is	  essential	  to	  assess	  exactly	  which	  contaminants	  may	  be	  acting	  upon	  the	  organisms	  so	  that	  their	  interactive	  effects	  may	  be	  determined.	  	  In	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that	  regard,	  further	  studies	  assessing	  other	  components	  of	  the	  oil	  would	  be	  environmentally	  relevant,	  although	  assessing	  the	  properties	  of	  individual	  components	  like	  this	  study	  has	  done	  with	  PAHs	  is	  equally	  important,	  as	  it	  contributes	  to	  further	  understanding	  the	  results	  of	  possible	  interaction	  effects.	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Appendix	  	  
Attachment	  1:	  Physiological	  data	  for	  the	  fish.	  	  
Sample	   Treatment	   Exposure	  (days)	   Weight	  (grams)	   Length	  (cm.)	  0T1	   Zero	   0	   28	   14	  0T2	   Zero	   0	   20	   13	  0T3	   Zero	   0	   17	   14	  0T4	   Zero	   0	   34	   16	  0T5	   Zero	   0	   35	   15	  0T6	   Zero	   0	   31	   14.5	  0T7	   Zero	   0	   22	   13.3	  0T8	   Zero	   0	   23	   13	  1T1	   Medium	   2	   31	   15.5	  1T2	   Low	   2	   33	   15.5	  1T3	   High	   2	   21	   14	  1T4	   Medium	   2	   54	   19	  1T5	   High	   2	   21	   14	  1T6	   Low	   2	   20	   13	  1T7	   Low	   2	   18	   13.5	  1T8	   High	   2	   28	   15.5	  1T9	   Control	   2	   35	   16	  1T10	   Low	   2	   58	   18.5	  1T11	   High	   2	   30	   16	  1T12	   High	   2	   70	   19	  1T13	   Medium	   2	   41	   18	  1T14	   Control	   2	   22	   15	  1T15	   Low	   2	   23	   14	  1T16	   Control	   2	   29	   15.5	  1T17	   Low	   2	   57	   19.3	  1T18	   Medium	   2	   31	   16	  1T19	   Control	   2	   18	   13	  1T20	   Control	   2	   26	   14.5	  1T21	   Medium	   2	   18	   13	  1T22	   High	   2	   57	   19	  1T23	   Control	   2	   25	   14.5	  1T24	   Medium	   2	   28	   15	  2T1	   Medium	   8	   44	   17	  2T2	   Low	   8	   34	   17.7	  2T3	   High	   8	   25	   14.7	  2T4	   Medium	   8	   25	   16	  2T5	   High	   8	   32	   16	  2T6	   Low	   8	   44	   18	  2T7	   Low	   8	   20	   14	  
	   51	  
2T8	   High	   8	   26	   15	  2T9	   Control	   8	   22	   14	  2T10	   Low	   8	   25	   14.5	  2T11	   High	   8	   29	   14.5	  2T12	   High	   8	   26	   16	  2T13	   Medium	   8	   38	   16.5	  2T14	   Control	   8	   61	   20	  2T15	   Low	   8	   46	   18	  2T16	   Control	   8	   32	   16	  2T17	   Low	   8	   39	   17	  2T18	   Medium	   8	   34	   17	  2T19	   Control	   8	   48	   18.5	  2T20	   Control	   8	   26	   15	  2T21	   Medium	   8	   21	   14	  2T22	   High	   8	   26	   15.5	  2T23	   Control	   8	   20	   14	  2T24	   Medium	   8	   20	   14.5	  3T1-­‐i	   Medium	   16	   23	   14	  3T1-­‐0	   Medium	   16	   31	   16	  3T3-­‐i	   High	   16	   31	   16	  3T3-­‐0	   High	   16	   23	   15	  3T5-­‐i	   High	   16	   25	   14	  3T5-­‐0	   High	   16	   54	   19	  3T6-­‐i	   Low	   16	   29	   16	  3T6-­‐0	   Low	   16	   25	   15	  3T7-­‐i	   Low	   16	   18	   14	  3T7-­‐0	   Low	   16	   13	   13	  3T9-­‐i	   Control	   16	   18	   13	  3T9-­‐0	   Control	   16	   37	   17	  3T10-­‐i	   Low	   16	   22	   14.5	  3T10-­‐0	   Low	   16	   21	   14	  3T11-­‐i	   High	   16	   21	   15	  3T11-­‐0	   High	   16	   44	   18.5	  3T12-­‐i	   High	   16	   51	   18.5	  3T12-­‐0	   High	   16	   21	   14.5	  3T13-­‐i	   Medium	   16	   29	   15.5	  3T13-­‐0	   Medium	   16	   25	   14.5	  3T15-­‐i	   Low	   16	   33	   16	  3T15-­‐0	   Low	   16	   24	   15	  3T16-­‐i	   Control	   16	   25	   15	  3T16-­‐0	   Control	   16	   32	   16	  3T19-­‐i	   Control	   16	   21	   13.5	  3T19-­‐0	   Control	   16	   25	   14.5	  3T20-­‐i	   Control	   16	   45	   18	  
	   52	  
3T20-­‐0	   Control	   16	   21	   14	  3T21-­‐i	   Medium	   16	   32	   16.5	  3T21-­‐0	   Medium	   16	   20	   14.5	  3T23-­‐i	   Control	   16	   42	   18	  3T23-­‐0	   Control	   16	   49	   18	  3T24-­‐i	   Medium	   16	   49	   18.5	  3T24-­‐0	   Medium	   16	   29	   15.5	  	  
Attachment	  2:	  Data	  for	  PAH	  metabolites	  in	  bile	  show	  as	  log10-­‐transformed	  concentrations.	  	  
Sample	   Treatment	   Exposure	  (days)	   OH-­‐Pyrene	   OH-­‐Phenatrene	  0T1	   Zero	   0	   	   	  0T2	   Zero	   0	   1.506288508	   0.781827153	  0T3	   Zero	   0	   1.405482963	   1.28474647	  0T4	   Zero	   0	   0.907303849	   0.972063916	  0T5	   Zero	   0	   	   	  0T6	   Zero	   0	   0.758381942	   0.846027675	  0T7	   Zero	   0	   0.206015877	   0.875061263	  0T8	   Zero	   0	   0.153509989	   1.195733648	  1T1	   Medium	   2	   	   	  1T2	   Low	   2	   2.724218506	   2.776425123	  1T3	   High	   2	   2.29992113	   2.888112069	  1T4	   Medium	   2	   2.890426608	   3.001430812	  1T5	   High	   2	   2.475424195	   3.162026432	  1T6	   Low	   2	   	   	  1T7	   Low	   2	   2.134718841	   2.720473536	  1T8	   High	   2	   1.473735068	   1.91392506	  1T9	   Control	   2	   0.846151477	   1.157879674	  1T10	   Low	   2	   	   	  1T11	   High	   2	   2.179034466	   2.917867708	  1T12	   High	   2	   2.551230355	   2.771183127	  1T13	   Medium	   2	   	   	  1T14	   Control	   2	   	   	  1T15	   Low	   2	   	   	  1T16	   Control	   2	   2.899711095	   1.713070326	  1T17	   Low	   2	   2.114977745	   2.748374113	  1T18	   Medium	   2	   2.49938462	   2.944102498	  1T19	   Control	   2	   1.368286885	   1.114610984	  1T20	   Control	   2	   2.612709703	   1.568201724	  1T21	   Medium	   2	   	   	  1T22	   High	   2	   2.991292544	   3.320769228	  1T23	   Control	   2	   1.377852419	   1.067256889	  1T24	   Medium	   2	   2.655455393	   3.07044425	  2T1	   Medium	   8	   2.3253925	   3.116972823	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2T2	   Low	   8	   2.098193626	   2.312980862	  2T3	   High	   8	   1.583493495	   2.346607217	  2T4	   Medium	   8	   2.339411687	   2.941238049	  2T5	   High	   8	   2.659906697	   3.443012511	  2T6	   Low	   8	   2.001387524	   2.413366831	  2T7	   Low	   8	   	   	  2T8	   High	   8	   2.652081878	   3.297979244	  2T9	   Control	   8	   0.089905111	   1.364888545	  2T10	   Low	   8	   2.37817979	   2.858928007	  2T11	   High	   8	   2.553506799	   3.284633733	  2T12	   High	   8	   2.354300562	   2.98311638	  2T13	   Medium	   8	   1.290857877	   1.868662068	  2T14	   Control	   8	   1.541529322	   1.098989639	  2T15	   Low	   8	   	   	  2T16	   Control	   8	   2.344470872	   1.310990527	  2T17	   Low	   8	   2.670681785	   3.240449399	  2T18	   Medium	   8	   2.537819095	   3.22331419	  2T19	   Control	   8	   0.919757781	   0.945862325	  2T20	   Control	   8	   1.524512957	   0.996424104	  2T21	   Medium	   8	   0.120573931	   2.764146232	  2T22	   High	   8	   2.890286853	   3.676547296	  2T23	   Control	   8	   0.710286648	   1.232894509	  2T24	   Medium	   8	   	   	  3T1-­‐i	   Medium	   16	  LPS	   2.195733482	   2.878462622	  3T1-­‐0	   Medium	   16	  PBS	   2.09684052	   2.849658916	  3T3-­‐i	   High	   16	  LPS	   2.093600864	   2.812175766	  3T3-­‐0	   High	   16	  PBS	   	   	  3T5-­‐i	   High	   16	  LPS	   1.113215123	   2.232085933	  3T5-­‐0	   High	   16	  PBS	   2.307987817	   2.64234579	  3T6-­‐i	   Low	   16	  LPS	   2.248856075	   2.410142616	  3T6-­‐0	   Low	   16	  PBS	   2.433529826	   2.77825981	  3T7-­‐i	   Low	   16	  LPS	   2.293747079	   2.481806538	  3T7-­‐0	   Low	   16	  PBS	   2.210184706	   2.574864314	  3T9-­‐i	   Control	   16	  LPS	   1.035503382	   1.091807597	  3T9-­‐0	   Control	   16	  PBS	   0.895129602	   1.06228107	  3T10-­‐i	   Low	   16	  LPS	   0.964923878	   2.065736525	  3T10-­‐0	   Low	   16	  PBS	   2.454234896	   2.665637267	  3T11-­‐i	   High	   16	  LPS	   2.593568598	   3.139289872	  3T11-­‐0	   High	   16	  PBS	   2.848416985	   3.553955807	  3T12-­‐i	   High	   16	  LPS	   	   	  3T12-­‐0	   High	   16	  PBS	   1.855785587	   2.437116093	  3T13-­‐i	   Medium	   16	  LPS	   2.364803026	   2.959587496	  3T13-­‐0	   Medium	   16	  PBS	   2.891219565	   3.496362205	  3T15-­‐i	   Low	   16	  LPS	   1.742847147	   2.420297435	  3T15-­‐0	   Low	   16	  PBS	   2.224636639	   2.699030801	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3T16-­‐i	   Control	   16	  LPS	   2.267503541	   1.563955465	  3T16-­‐0	   Control	   16	  PBS	   1.305759672	   0.446070936	  3T19-­‐i	   Control	   16	  LPS	   1.035689411	   0.834166284	  3T19-­‐0	   Control	   16	  PBS	   1.443231686	   1.198024426	  3T20-­‐i	   Control	   16	  LPS	   1.605738383	   1.085647288	  3T20-­‐0	   Control	   16	  PBS	   2.121953584	   1.383671774	  3T21-­‐i	   Medium	   16	  LPS	   2.223050998	   2.637271527	  3T21-­‐0	   Medium	   16	  PBS	   2.562518877	   3.104213884	  3T23-­‐i	   Control	   16	  LPS	   0.988645856	   1.203386492	  3T23-­‐0	   Control	   16	  PBS	   0.570391144	   0.950316164	  3T24-­‐i	   Medium	   16	  LPS	   2.290955595	   2.931030486	  3T24-­‐0	   Medium	   16	  PBS	   	   	  	  
Attachment	  3:	  Data	  for	  EROD	  activity	  shown	  as	  log10-­‐transformed	  concentrations.	  	  
Sample	   Treatment	   Exposure	  (days)	   EROD	  pmol/min/mg	  protein	  0T1	   Zero	   0	   0.965842708	  0T2	   Zero	   0	   1.599555591	  0T3	   Zero	   0	   1.608512222	  0T4	   Zero	   0	   1.581452594	  0T5	   Zero	   0	   1.365487985	  0T6	   Zero	   0	   1.572775267	  0T7	   Zero	   0	   1.239920365	  0T8	   Zero	   0	   1.641226736	  1T1	   Medium	   2	   1.902131404	  1T2	   Low	   2	   1.699206759	  1T3	   High	   2	   1.917711991	  1T4	   Medium	   2	   2.075183533	  1T5	   High	   2	   1.205091478	  1T6	   Low	   2	   2.140225125	  1T7	   Low	   2	   2.038262407	  1T8	   High	   2	   1.776658813	  1T9	   Control	   2	   1.821665151	  1T10	   Low	   2	   1.898939767	  1T11	   High	   2	   2.2122287	  1T12	   High	   2	   1.669476289	  1T13	   Medium	   2	   1.840443652	  1T14	   Control	   2	   1.698448856	  1T15	   Low	   2	   2.086967781	  1T16	   Control	   2	   0.755780868	  1T17	   Low	   2	   1.966573435	  1T18	   Medium	   2	   2.120718077	  1T19	   Control	   2	   1.591162576	  1T20	   Control	   2	   1.530176586	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1T21	   Medium	   2	   1.749817889	  1T22	   High	   2	   2.133785142	  1T23	   Control	   2	   1.374198258	  1T24	   Medium	   2	   1.699499353	  2T1	   Medium	   8	   1.758034256	  2T2	   Low	   8	   2.290279529	  2T3	   High	   8	   2.005277906	  2T4	   Medium	   8	   1.841174758	  2T5	   High	   8	   1.869013265	  2T6	   Low	   8	   1.787678908	  2T7	   Low	   8	   2.372460841	  2T8	   High	   8	   1.483913203	  2T9	   Control	   8	   1.436006539	  2T10	   Low	   8	   1.766351481	  2T11	   High	   8	   1.851416724	  2T12	   High	   8	   2.036036042	  2T13	   Medium	   8	   1.912045414	  2T14	   Control	   8	   1.385461088	  2T15	   Low	   8	   1.677443397	  2T16	   Control	   8	   1.167421183	  2T17	   Low	   8	   1.962340212	  2T18	   Medium	   8	   2.147094368	  2T19	   Control	   8	   0.970811611	  2T20	   Control	   8	   1.491476074	  2T21	   Medium	   8	   1.977439207	  2T22	   High	   8	   1.912228894	  2T23	   Control	   8	   1.45274578	  2T24	   Medium	   8	   1.896641461	  3T1-­‐i	   Medium	   16	  LPS	   2.124145824	  3T1-­‐0	   Medium	   16	  PBS	   1.904158148	  3T3-­‐i	   High	   16	  LPS	   2.419292682	  3T3-­‐0	   High	   16	  PBS	   1.8109714	  3T5-­‐i	   High	   16	  LPS	   1.918644262	  3T5-­‐0	   High	   16	  PBS	   1.573556562	  3T6-­‐i	   Low	   16	  LPS	   1.741356848	  3T6-­‐0	   Low	   16	  PBS	   1.638969997	  3T7-­‐i	   Low	   16	  LPS	   1.287186268	  3T7-­‐0	   Low	   16	  PBS	   1.302378187	  3T9-­‐i	   Control	   16	  LPS	   1.634081201	  3T9-­‐0	   Control	   16	  PBS	   1.727064305	  3T10-­‐i	   Low	   16	  LPS	   1.92633167	  3T10-­‐0	   Low	   16	  PBS	   1.777032467	  3T11-­‐i	   High	   16	  LPS	   1.986547813	  3T11-­‐0	   High	   16	  PBS	   1.83491388	  3T12-­‐i	   High	   16	  LPS	   1.655258803	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3T12-­‐0	   High	   16	  PBS	   2.180956951	  3T13-­‐i	   Medium	   16	  LPS	   1.871948594	  3T13-­‐0	   Medium	   16	  PBS	   1.878975211	  3T15-­‐i	   Low	   16	  LPS	   1.875749472	  3T15-­‐0	   Low	   16	  PBS	   1.86294085	  3T16-­‐i	   Control	   16	  LPS	   1.912506309	  3T16-­‐0	   Control	   16	  PBS	   1.851632408	  3T19-­‐i	   Control	   16	  LPS	   0.849993233	  3T19-­‐0	   Control	   16	  PBS	   1.496111114	  3T20-­‐i	   Control	   16	  LPS	   1.422798053	  3T20-­‐0	   Control	   16	  PBS	   0.938478449	  3T21-­‐i	   Medium	   16	  LPS	   1.815727984	  3T21-­‐0	   Medium	   16	  PBS	   1.736558972	  3T23-­‐i	   Control	   16	  LPS	   1.217834624	  3T23-­‐0	   Control	   16	  PBS	   1.414304688	  3T24-­‐i	   Medium	   16	  LPS	   2.050055386	  3T24-­‐0	   Medium	   16	  PBS	   1.934205226	  	  
Attachment	  4:	  Data	  for	  CYP1A	  levels	  from	  the	  ELISA	  assay,	  shown	  as	  log10-­‐transformed	  mean	  optical	  density.	  	  
Sample	   Treatment	   Exposure	  (days)	   Mean	  optical	  density	  0T1	   Zero	   0	   -­‐0.339134522	  0T2	   Zero	   0	   -­‐0.274905479	  0T3	   Zero	   0	   -­‐1.084738074	  0T4	   Zero	   0	   -­‐0.37675071	  0T5	   Zero	   0	   -­‐0.852840986	  0T6	   Zero	   0	   -­‐0.417936637	  0T7	   Zero	   0	   -­‐0.8403922	  0T8	   Zero	   0	   -­‐0.623708419	  1T1	   Medium	   2	   -­‐0.344110489	  1T2	   Low	   2	   -­‐0.311580178	  1T3	   High	   2	   0.125262458	  1T4	   Medium	   2	   0.213783299	  1T5	   High	   2	   0.217747073	  1T6	   Low	   2	   -­‐0.137074318	  1T7	   Low	   2	   0.094121596	  1T8	   High	   2	   0.210012629	  1T9	   Control	   2	   -­‐1.295281401	  1T10	   Low	   2	   -­‐0.034242807	  1T11	   High	   2	   -­‐0.249491605	  1T12	   High	   2	   -­‐0.266911532	  1T13	   Medium	   2	   -­‐0.481400839	  1T14	   Control	   2	   -­‐1.109237515	  1T15	   Low	   2	   0.006552455	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1T16	   Control	   2	   -­‐0.521129586	  1T17	   Low	   2	   0.071570269	  1T18	   Medium	   2	   -­‐0.271646218	  1T19	   Control	   2	   0.165541077	  1T20	   Control	   2	   -­‐0.881769341	  1T21	   Medium	   2	   -­‐0.485736387	  1T22	   High	   2	   -­‐0.007382363	  1T23	   Control	   2	   -­‐0.795875528	  1T24	   Medium	   2	   -­‐0.335358024	  2T1	   Medium	   8	   -­‐0.48366701	  2T2	   Low	   8	   0.072556091	  2T3	   High	   8	   0.178079194	  2T4	   Medium	   8	   0.018509341	  2T5	   High	   8	   0.214846871	  2T6	   Low	   8	   -­‐0.305131898	  2T7	   Low	   8	   0.382377303	  2T8	   High	   8	   -­‐0.029212977	  2T9	   Control	   8	   -­‐0.599208655	  2T10	   Low	   8	   -­‐0.262514591	  2T11	   High	   8	   0.085087852	  2T12	   High	   8	   -­‐0.031050319	  2T13	   Medium	   8	   0.073806552	  2T14	   Control	   8	   -­‐0.686879104	  2T15	   Low	   8	   -­‐0.491061592	  2T16	   Control	   8	   -­‐0.991319121	  2T17	   Low	   8	   -­‐0.051098465	  2T18	   Medium	   8	   0.167317335	  2T19	   Control	   8	   -­‐0.481223157	  2T20	   Control	   8	   -­‐0.485969593	  2T21	   Medium	   8	   0.098989639	  2T22	   High	   8	   0.240433564	  2T23	   Control	   8	   -­‐0.649751982	  2T24	   Medium	   8	   -­‐0.106964377	  3T1-­‐i	   Medium	   16	  LPS	   -­‐0.363725706	  3T1-­‐0	   Medium	   16	  PBS	   0.230704314	  3T3-­‐i	   High	   16	  LPS	   -­‐0.091346232	  3T3-­‐0	   High	   16	  PBS	   -­‐0.123976126	  3T5-­‐i	   High	   16	  LPS	   0.174563914	  3T5-­‐0	   High	   16	  PBS	   -­‐0.442510451	  3T6-­‐i	   Low	   16	  LPS	   -­‐0.177178355	  3T6-­‐0	   Low	   16	  PBS	   -­‐0.084430599	  3T7-­‐i	   Low	   16	  LPS	   -­‐0.162945697	  3T7-­‐0	   Low	   16	  PBS	   -­‐0.140261434	  3T9-­‐i	   Control	   16	  LPS	   -­‐1.059070902	  3T9-­‐0	   Control	   16	  PBS	   -­‐0.445345186	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3T10-­‐i	   Low	   16	  LPS	   -­‐0.079027576	  3T10-­‐0	   Low	   16	  PBS	   -­‐0.009047887	  3T11-­‐i	   High	   16	  LPS	   -­‐0.463436294	  3T11-­‐0	   High	   16	  PBS	   -­‐0.154060899	  3T12-­‐i	   High	   16	  LPS	   -­‐0.094646682	  3T12-­‐0	   High	   16	  PBS	   0.128669509	  3T13-­‐i	   Medium	   16	  LPS	   0.169968174	  3T13-­‐0	   Medium	   16	  PBS	   -­‐0.07305998	  3T15-­‐i	   Low	   16	  LPS	   -­‐0.165609917	  3T15-­‐0	   Low	   16	  PBS	   -­‐0.425715638	  3T16-­‐i	   Control	   16	  LPS	   -­‐0.46183173	  3T16-­‐0	   Control	   16	  PBS	   -­‐0.490768475	  3T19-­‐i	   Control	   16	  LPS	   -­‐0.401497569	  3T19-­‐0	   Control	   16	  PBS	   -­‐0.684060856	  3T20-­‐i	   Control	   16	  LPS	   -­‐0.65338317	  3T20-­‐0	   Control	   16	  PBS	   -­‐0.514414577	  3T21-­‐i	   Medium	   16	  LPS	   0.019455633	  3T21-­‐0	   Medium	   16	  PBS	   -­‐0.05207638	  3T23-­‐i	   Control	   16	  LPS	   -­‐0.413118395	  3T23-­‐0	   Control	   16	  PBS	   -­‐0.990355092	  3T24-­‐i	   Medium	   16	  LPS	   0.221722938	  3T24-­‐0	   Medium	   16	  PBS	   -­‐0.249491605	  	  	  
Attachment	  5:	  Data	  for	  DNA	  damage	  shown	  as	  log10-­‐transformed	  median	  tail	  intensity	  (TI).	  	  
Sample	   Treatment	   Tissue	   Injection	   Exposure	  (days)	   Median	  TI	  0T1	   Zero	   Blood	   -­‐	   0	   1.5608381	  0T2	   Zero	   Blood	   -­‐	   0	   0.353907107	  0T3	   Zero	   Blood	   -­‐	   0	   0.036436755	  0T4	   Zero	   Blood	   -­‐	   0	   0.393617633	  0T5	   Zero	   Blood	   -­‐	   0	   1.388659866	  0T6	   Zero	   Blood	   -­‐	   0	   0.896123884	  0T7	   Zero	   Blood	   -­‐	   0	   0.340339325	  0T8	   Zero	   Blood	   -­‐	   0	   0.390806453	  1T1	   Medium	   Blood	   -­‐	   2	   1.529511741	  1T2	   Low	   Blood	   -­‐	   2	   0.388144509	  1T3	   High	   Blood	   -­‐	   2	   0.702288744	  1T4	   Medium	   Blood	   -­‐	   2	   0.630964063	  1T5	   High	   Blood	   -­‐	   2	   -­‐0.94875419	  1T6	   Low	   Blood	   -­‐	   2	   1.88975093	  1T7	   Low	   Blood	   -­‐	   2	   1.122105469	  1T8	   High	   Blood	   -­‐	   2	   1.11617234	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1T9	   Control	   Blood	   -­‐	   2	   1.322129748	  1T10	   Low	   Blood	   -­‐	   2	   0.074661508	  1T11	   High	   Blood	   -­‐	   2	   1.330063467	  1T12	   High	   Blood	   -­‐	   2	   0.377124553	  1T13	   Medium	   Blood	   -­‐	   2	   0.510311778	  1T14	   Control	   Blood	   -­‐	   2	   1.481575922	  1T15	   Low	   Blood	   -­‐	   2	   1.562788835	  1T16	   Control	   Blood	   -­‐	   2	   1.944228649	  1T17	   Low	   Blood	   -­‐	   2	   1.952771522	  1T18	   Medium	   Blood	   -­‐	   2	   0.032377731	  1T19	   Control	   Blood	   -­‐	   2	   1.944634944	  1T20	   Control	   Blood	   -­‐	   2	   1.768627809	  1T21	   Medium	   Blood	   -­‐	   2	   0.862193688	  1T22	   High	   Blood	   -­‐	   2	   1.736601282	  1T23	   Control	   Blood	   -­‐	   2	   1.386397738	  1T24	   Medium	   Blood	   -­‐	   2	   1.935169595	  2T1	   Medium	   Blood	   -­‐	   8	   0.086866824	  2T2	   Low	   Blood	   -­‐	   8	   0.849686819	  2T3	   High	   Blood	   -­‐	   8	   -­‐0.245399042	  2T4	   Medium	   Blood	   -­‐	   8	   0.515642966	  2T5	   High	   Blood	   -­‐	   8	   -­‐0.412894224	  2T6	   Low	   Blood	   -­‐	   8	   0.407715733	  2T7	   Low	   Blood	   -­‐	   8	   0.163186992	  2T8	   High	   Blood	   -­‐	   8	   -­‐0.115862869	  2T9	   Control	   Blood	   -­‐	   8	   0.101860642	  2T10	   Low	   Blood	   -­‐	   8	   1.768086135	  2T11	   High	   Blood	   -­‐	   8	   1.896052816	  2T12	   High	   Blood	   -­‐	   8	   1.916637545	  2T13	   Medium	   Blood	   -­‐	   8	   1.470687004	  2T14	   Control	   Blood	   -­‐	   8	   1.898865406	  2T15	   Low	   Blood	   -­‐	   8	   1.925451901	  2T16	   Control	   Blood	   -­‐	   8	   1.748473948	  2T17	   Low	   Blood	   -­‐	   8	   -­‐0.888909985	  2T18	   Medium	   Blood	   -­‐	   8	   -­‐0.778086287	  2T19	   Control	   Blood	   -­‐	   8	   -­‐1.0084601	  2T20	   Control	   Blood	   -­‐	   8	   -­‐1.258837461	  2T21	   Medium	   Blood	   -­‐	   8	   -­‐0.591889226	  2T22	   High	   Blood	   -­‐	   8	   -­‐0.859911191	  2T23	   Control	   Blood	   -­‐	   8	   -­‐0.408139114	  2T24	   Medium	   Blood	   -­‐	   8	   -­‐1.60886624	  3T1-­‐i	   Medium	   Blood	   LPS	   16	   0.786666898	  3T1-­‐0	   Medium	   Blood	   PBS	   16	   1.263365469	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3T3-­‐i	   High	   Blood	   LPS	   16	   1.863632964	  3T3-­‐0	   High	   Blood	   PBS	   16	   1.823469552	  3T5-­‐i	   High	   Blood	   LPS	   16	   0.115784498	  3T5-­‐0	   High	   Blood	   PBS	   16	   0.403709659	  3T6-­‐i	   Low	   Blood	   LPS	   16	   0.849306312	  3T6-­‐0	   Low	   Blood	   PBS	   16	   0.280874628	  3T7-­‐i	   Low	   Blood	   LPS	   16	   0.380435541	  3T7-­‐0	   Low	   Blood	   PBS	   16	   1.524493094	  3T9-­‐i	   Control	   Blood	   LPS	   16	   0.483053934	  3T9-­‐0	   Control	   Blood	   PBS	   16	   0.505429873	  3T10-­‐i	   Low	   Blood	   LPS	   16	   1.610172582	  3T10-­‐0	   Low	   Blood	   PBS	   16	   1.389648725	  3T11-­‐i	   High	   Blood	   LPS	   16	   0.280889394	  3T11-­‐0	   High	   Blood	   PBS	   16	   0.714964589	  3T12-­‐i	   High	   Blood	   LPS	   16	   -­‐0.175114888	  3T12-­‐0	   High	   Blood	   PBS	   16	   0.508485288	  3T13-­‐i	   Medium	   Blood	   LPS	   16	   0.641963877	  3T13-­‐0	   Medium	   Blood	   PBS	   16	   0.222991567	  3T15-­‐i	   Low	   Blood	   LPS	   16	   0.487737168	  3T15-­‐0	   Low	   Blood	   PBS	   16	   0.179006919	  3T16-­‐i	   Control	   Blood	   LPS	   16	   -­‐0.47978217	  3T16-­‐0	   Control	   Blood	   PBS	   16	   1.312034044	  3T19-­‐i	   Control	   Blood	   LPS	   16	   0.179529028	  3T19-­‐0	   Control	   Blood	   PBS	   16	   -­‐0.289510401	  3T20-­‐i	   Control	   Blood	   LPS	   16	   0.297832554	  3T20-­‐0	   Control	   Blood	   PBS	   16	   -­‐0.406069678	  3T21-­‐i	   Medium	   Blood	   LPS	   16	   1.809614379	  3T21-­‐0	   Medium	   Blood	   PBS	   16	   -­‐0.013086642	  3T23-­‐i	   Control	   Blood	   LPS	   16	   -­‐0.587163904	  3T23-­‐0	   Control	   Blood	   PBS	   16	   -­‐0.127424384	  3T24-­‐i	   Medium	   Blood	   LPS	   16	   -­‐0.076557913	  3T24-­‐0	   Medium	   Blood	   PBS	   16	   1.457800123	  0T1N	   Zero	   Kidney	   -­‐	   0	   1.119720426	  0T2N	   Zero	   Kidney	   -­‐	   0	   0.846087513	  0T3N	   Zero	   Kidney	   -­‐	   0	   1.361561944	  0T4N	   Zero	   Kidney	   -­‐	   0	   0.035277769	  0T5N	   Zero	   Kidney	   -­‐	   0	   1.028822952	  0T6N	   Zero	   Kidney	   -­‐	   0	   0.797511304	  0T7N	   Zero	   Kidney	   -­‐	   0	   -­‐0.190507667	  0T8N	   Zero	   Kidney	   -­‐	   0	   0.750156793	  1T1N	   Medium	   Kidney	   -­‐	   2	   -­‐1.588917266	  1T2N	   Low	   Kidney	   -­‐	   2	   -­‐1.037941971	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1T3N	   High	   Kidney	   -­‐	   2	   1.550641908	  1T4N	   Medium	   Kidney	   -­‐	   2	   1.687633153	  1T5N	   High	   Kidney	   -­‐	   2	   1.176290932	  1T6N	   Low	   Kidney	   -­‐	   2	   1.805524813	  1T7N	   Low	   Kidney	   -­‐	   2	   1.479747966	  1T8N	   High	   Kidney	   -­‐	   2	   1.349217294	  1T9N	   Control	   Kidney	   -­‐	   2	   1.941491418	  1T10N	   Low	   Kidney	   -­‐	   2	   1.948028252	  1T11N	   High	   Kidney	   -­‐	   2	   -­‐0.164327348	  1T12N	   High	   Kidney	   -­‐	   2	   0.87666011	  1T13N	   Medium	   Kidney	   -­‐	   2	   1.690653488	  1T14N	   Control	   Kidney	   -­‐	   2	   1.800976679	  1T15N	   Low	   Kidney	   -­‐	   2	   0.654048346	  1T16N	   Control	   Kidney	   -­‐	   2	   1.093595394	  1T17N	   Low	   Kidney	   -­‐	   2	   0.593784401	  1T18N	   Medium	   Kidney	   -­‐	   2	   1.939853694	  1T19N	   Control	   Kidney	   -­‐	   2	   -­‐0.129769229	  1T20N	   Control	   Kidney	   -­‐	   2	   -­‐0.29201621	  1T21N	   Medium	   Kidney	   -­‐	   2	   -­‐0.351487584	  1T22N	   High	   Kidney	   -­‐	   2	   	  1T23N	   Control	   Kidney	   -­‐	   2	   1.347349612	  1T24N	   Medium	   Kidney	   -­‐	   2	   1.103541357	  2T1N	   Medium	   Kidney	   -­‐	   8	   1.468434907	  2T2N	   Low	   Kidney	   -­‐	   8	   -­‐0.908288142	  2T3N	   High	   Kidney	   -­‐	   8	   1.456642197	  2T4N	   Medium	   Kidney	   -­‐	   8	   -­‐0.768808332	  2T5N	   High	   Kidney	   -­‐	   8	   0.415230451	  2T6N	   Low	   Kidney	   -­‐	   8	   0.254201637	  2T7N	   Low	   Kidney	   -­‐	   8	   0.260951621	  2T8N	   High	   Kidney	   -­‐	   8	   0.040547171	  2T9N	   Control	   Kidney	   -­‐	   8	   1.747905908	  2T10N	   Low	   Kidney	   -­‐	   8	   1.922473196	  2T11N	   High	   Kidney	   -­‐	   8	   1.771805187	  2T12N	   High	   Kidney	   -­‐	   8	   1.91242622	  2T13N	   Medium	   Kidney	   -­‐	   8	   1.39585193	  2T14N	   Control	   Kidney	   -­‐	   8	   1.782417891	  2T15N	   Low	   Kidney	   -­‐	   8	   1.80681067	  2T16N	   Control	   Kidney	   -­‐	   8	   1.888265669	  2T17N	   Low	   Kidney	   -­‐	   8	   -­‐0.533171063	  2T18N	   Medium	   Kidney	   -­‐	   8	   -­‐0.335133771	  2T19N	   Control	   Kidney	   -­‐	   8	   -­‐0.865521551	  2T20N	   Control	   Kidney	   -­‐	   8	   -­‐0.3478374	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2T21N	   Medium	   Kidney	   -­‐	   8	   -­‐0.671214201	  2T22N	   High	   Kidney	   -­‐	   8	   -­‐1.335361662	  2T23N	   Control	   Kidney	   -­‐	   8	   -­‐0.694688323	  2T24N	   Medium	   Kidney	   -­‐	   8	   -­‐1.372599473	  3T1N-­‐i	   Medium	   Kidney	   LPS	   16	   -­‐0.284072506	  3T1N-­‐0	   Medium	   Kidney	   PBS	   16	   -­‐0.013620652	  3T3N-­‐i	   High	   Kidney	   LPS	   16	   -­‐0.0531566	  3T3N-­‐0	   High	   Kidney	   PBS	   16	   0.118502645	  3T5N-­‐i	   High	   Kidney	   LPS	   16	   -­‐0.17180914	  3T5N-­‐0	   High	   Kidney	   PBS	   16	   0.391136311	  3T6N-­‐i	   Low	   Kidney	   LPS	   16	   -­‐0.392013103	  3T6N-­‐0	   Low	   Kidney	   PBS	   16	   -­‐0.513968248	  3T7N-­‐i	   Low	   Kidney	   LPS	   16	   -­‐0.372943448	  3T7N-­‐0	   Low	   Kidney	   PBS	   16	   0.336875033	  3T9N-­‐i	   Control	   Kidney	   LPS	   16	   1.540810157	  3T9N-­‐0	   Control	   Kidney	   PBS	   16	   1.698401368	  3T10N-­‐i	   Low	   Kidney	   LPS	   16	   1.544917026	  3T10N-­‐0	   Low	   Kidney	   PBS	   16	   1.483538935	  3T11N-­‐i	   High	   Kidney	   LPS	   16	   1.238497164	  3T11N-­‐0	   High	   Kidney	   PBS	   16	   -­‐0.010783741	  3T12N-­‐i	   High	   Kidney	   LPS	   16	   1.108668497	  3T12N-­‐0	   High	   Kidney	   PBS	   16	   1.62326155	  3T13N-­‐i	   Medium	   Kidney	   LPS	   16	   1.597261646	  3T13N-­‐0	   Medium	   Kidney	   PBS	   16	   1.441594232	  3T15N-­‐i	   Low	   Kidney	   LPS	   16	   1.118363602	  3T15N-­‐0	   Low	   Kidney	   PBS	   16	   0.877650929	  3T16N-­‐i	   Control	   Kidney	   LPS	   16	   0.735993686	  3T16N-­‐0	   Control	   Kidney	   PBS	   16	   1.42943146	  3T19N-­‐i	   Control	   Kidney	   LPS	   16	   -­‐0.186857347	  3T19N-­‐0	   Control	   Kidney	   PBS	   16	   0.069509457	  3T20N-­‐i	   Control	   Kidney	   LPS	   16	   1.51856762	  3T20N-­‐0	   Control	   Kidney	   PBS	   16	   0.014277072	  3T21N-­‐i	   Medium	   Kidney	   LPS	   16	   -­‐0.01451081	  3T21N-­‐0	   Medium	   Kidney	   PBS	   16	   -­‐0.07648276	  3T23N-­‐i	   Control	   Kidney	   LPS	   16	   0.765660522	  3T23N-­‐0	   Control	   Kidney	   PBS	   16	   0.086175336	  3T24N-­‐i	   Medium	   Kidney	   LPS	   16	   1.177289751	  3T24N-­‐0	   Medium	   Kidney	   PBS	   16	   1.442789171	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Attachment	  6:	  Respiratory	  burst	  data	  shown	  as	  log10-­‐transformed	  H2O2	  production	  stimulated	  with	  PMA	  and	  without	  PMA.	  	  
Sample	   Treatment	   Exposure	  
(days)	  
H2O2	  production	  NO	  
PMA	  
H2O2	  production	  
PMA	  0T1	   Zero	   0	   0.354108439	   1.226342087	  0T2	   Zero	   0	   1.097604329	   1.694780636	  0T3	   Zero	   0	   0.753583059	   0.773786445	  0T4	   Zero	   0	   1.65040467	   1.532372134	  0T5	   Zero	   0	   -­‐0.26760624	   0.649334859	  0T6	   Zero	   0	   0.252853031	   0.413299764	  0T7	   Zero	   0	   1.230193379	   1.266231697	  0T8	   Zero	   0	   2.564879018	   2.452108584	  1T1	   Medium	   2	   	   0.506505032	  1T2	   Low	   2	   -­‐1.22184875	   -­‐2	  1T3	   High	   2	   	   0.372912003	  1T4	   Medium	   2	   0.456366033	   0.117271296	  1T5	   High	   2	   -­‐0.187086643	   0.434568904	  1T6	   Low	   2	   -­‐0.214670165	   0.56937391	  1T7	   Low	   2	   -­‐0.721246399	   0.737192643	  1T8	   High	   2	   0.252853031	   -­‐0.455931956	  1T9	   Control	   2	   	   0.598790507	  1T10	   Low	   2	   0.230448921	   -­‐0.27572413	  1T11	   High	   2	   	   -­‐0.744727495	  1T12	   High	   2	   0.340444115	   0.170261715	  1T13	   Medium	   2	   	   -­‐0.080921908	  1T14	   Control	   2	   	   	  1T15	   Low	   2	   	   	  1T16	   Control	   2	   	   	  1T17	   Low	   2	   -­‐0.26760624	   0.045322979	  1T18	   Medium	   2	   -­‐0.193820026	   -­‐0.187086643	  1T19	   Control	   2	   -­‐0.236572006	   -­‐0.337242168	  1T20	   Control	   2	   0.075546961	   -­‐0.292429824	  1T21	   Medium	   2	   0.98811284	   1.180985581	  1T22	   High	   2	   1.115610512	   1.061829307	  1T23	   Control	   2	   1.091666958	   1.744762237	  1T24	   Medium	   2	   1.211921084	   1.0923697	  2T1	   Medium	   8	   0.477121255	   0.722633923	  2T2	   Low	   8	   0.698970004	   0.344392274	  2T3	   High	   8	   -­‐0.055517328	   -­‐0.091514981	  2T4	   Medium	   8	   0.264817823	   -­‐0.431798276	  2T5	   High	   8	   0.526339277	   1.055760465	  2T6	   Low	   8	   0.706717782	   0.809559715	  2T7	   Low	   8	   -­‐0.259637311	   0.401400541	  2T8	   High	   8	   0.356025857	   0.041392685	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2T9	   Control	   8	   0.041392685	   0.645422269	  2T10	   Low	   8	   0.80685803	   1.171141151	  2T11	   High	   8	   0.195899652	   0.413299764	  2T12	   High	   8	   0.378397901	   0.646403726	  2T13	   Medium	   8	   0.330413773	   1.123524981	  2T14	   Control	   8	   1.053078444	   1.546542664	  2T15	   Low	   8	   0.797959644	   1.437274797	  2T16	   Control	   8	   0.774516966	   1.172894698	  2T17	   Low	   8	   	   	  2T18	   Medium	   8	   	   	  2T19	   Control	   8	   	   	  2T20	   Control	   8	   	   	  2T21	   Medium	   8	   	   	  2T22	   High	   8	   	   	  2T23	   Control	   8	   	   	  2T24	   Medium	   8	   	   	  3T1-­‐i	   Medium	   16	  LPS	   1.769451179	   1.97183228	  3T1-­‐0	   Medium	   16	  PBS	   1.178401342	   1.081347308	  3T3-­‐i	   High	   16	  LPS	   0.954724791	   0.859138297	  3T3-­‐0	   High	   16	  PBS	   1.308350949	   1.079181246	  3T5-­‐i	   High	   16	  LPS	   1.780389329	   1.916348652	  3T5-­‐0	   High	   16	  PBS	   2.040246215	   1.944137073	  3T6-­‐i	   Low	   16	  LPS	   1.940616082	   1.89580915	  3T6-­‐0	   Low	   16	  PBS	   1.915610863	   1.869349081	  3T7-­‐i	   Low	   16	  LPS	   2.001647191	   2.084111352	  3T7-­‐0	   Low	   16	  PBS	   1.547282308	   1.532117116	  3T9-­‐i	   Control	   16	  LPS	   1.743744879	   2.228528677	  3T9-­‐0	   Control	   16	  PBS	   -­‐0.420216403	   0.703291378	  3T10-­‐i	   Low	   16	  LPS	   0.255272505	   0.198657087	  3T10-­‐0	   Low	   16	  PBS	   1.276691529	   0.530199698	  3T11-­‐i	   High	   16	  LPS	   1.801952235	   2.121756759	  3T11-­‐0	   High	   16	  PBS	   0.722633923	   0.902546779	  3T12-­‐i	   High	   16	  LPS	   1.603144373	   1.671450554	  3T12-­‐0	   High	   16	  PBS	   1.511616021	   1.220369633	  3T13-­‐i	   Medium	   16	  LPS	   1.217483944	   1.757623746	  3T13-­‐0	   Medium	   16	  PBS	   1.072984745	   1.164055292	  3T15-­‐i	   Low	   16	  LPS	   1.32407658	   1.40534636	  3T15-­‐0	   Low	   16	  PBS	   1.842921121	   1.653115993	  3T16-­‐i	   Control	   16	  LPS	   2.211414245	   2.383635868	  3T16-­‐0	   Control	   16	  PBS	   1.903903527	   1.970579306	  3T19-­‐i	   Control	   16	  LPS	   0.290034611	   -­‐0.124938737	  3T19-­‐0	   Control	   16	  PBS	   1.120902818	   1.009450896	  3T20-­‐i	   Control	   16	  LPS	   0.766412847	   0.51054501	  3T20-­‐0	   Control	   16	  PBS	   1.388633969	   1.395501124	  3T21-­‐i	   Medium	   16	  LPS	   0.530199698	   0.934498451	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3T21-­‐0	   Medium	   16	  PBS	   1.136403448	   1.172310969	  3T23-­‐i	   Control	   16	  LPS	   0.397940009	   	  3T23-­‐0	   Control	   16	  PBS	   1.845779967	   1.810098041	  3T24-­‐i	   Medium	   16	  LPS	   1.574147064	   1.713490543	  3T24-­‐0	   Medium	   16	  PBS	   0.903632516	   0.946452265	  	  	  
Attachment	  7:	  Chemicals	  	  
Chemical	   Product	  No	   Producer	  Bovine	  serum	  albumin	   A7030	   Sigma-­‐Aldrich	  Carbonate-­‐bicarbonate	  buffer	  (capsule)	   C3041	   Sigma-­‐Aldrich	  Copper	  tartrate	  solution	  (reagent	  A)	   500-­‐0113	   Bio-­‐Rad	  Dichloromethane	   	   	  Dimethyl	  sulfoxide	   0231	   Amresco	  DL-­‐Dithiotreitol	   43819	   Fluka	  Analytic	  Ethylenediaminetatraacetic	  acid	  solution	   03690	   Fluka	  Analytic	  Folin	  reagent	  (reagent	  B)	   500-­‐0114	   Bio-­‐Rad	  Glutaraldehyde	   	   Sigma-­‐Aldrich	  Glycerol	   G5516	   Sigma-­‐Aldrich	  Goat	  anti-­‐rabbit	  IgG	  conjugated	  with	  HRP,	  GAR-­‐HRP	   L99496153-­‐001	   Biosense	  Laboratories	  Heparin	   H3393	   Sigma-­‐Aldrich	  Horseradish	  peroxidase	  (HRP)	   P8125	   Sigma-­‐Aldrich	  Hydrogen	  peroxide	  solution	  (30%)	   216763	   Sigma-­‐Aldrich	  L15	  Leibovitz	   L4386	   Sigma-­‐Aldrich	  LMP	  agarose	   A9414	   Sigma-­‐Aldrich	  Methanol	   322131	   Sigma-­‐Aldrich	  Percoll	   17-­‐0891-­‐01	   GE	  Healthcare	  Phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	   P8139	   Sigma-­‐Aldrich	  Potassium	  chloride	   1.04936.1000	   Merck	  Potassium	  phosphate	  dibasic	   221317	   Sigma-­‐Aldrich	  Potassium	  phosphate	  monobasic	   P5379	   Sigma-­‐Aldrich	  Rabbit-­‐anti-­‐fish	  CYP1A	  antibody	   CO2401201-­‐500	   Biosense	  Laboratories	  AS	  Resorufin	  ethyl	  ether	   E3763	   Sigma-­‐Aldrich	  Resorufin	  sodium	  salt	   R3257	   Sigma-­‐Aldrich	  Sodium	  dihydrogenphosphate	   71504	   Sigma-­‐Aldrich	  Sodium	  phosphate	  dibasic	   S5136	   Sigma-­‐Aldrich	  SyberGold	   	   	  Tetramethylbenzidine	  liquid	  substrate	  (TMB)	   4395L	   Kem	  En	  Tec	  Diagnostics	  Triphenylamine	   92930	   Fluka	  Analytics	  Triton	  X-­‐100	   1001054580	   Sigma-­‐Aldrich	  Trizma	  base	   T-­‐1503	   Sigma-­‐Aldrich	  Trizma	  hydrochloride	   T3253	   Sigma-­‐Aldrich	  Tryphan-­‐blue	   	   Invitrogen	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Tween-­‐20	   P1379	   Sigma-­‐Aldrich	  β-­‐glucoronidase/aryl	  sulphatase	   1.04114.0002	   Merck	  β-­‐NADPH	  reduced	  tetrasodium	  salt	   N1630	   Sigma-­‐Aldrich	  	   	   	  	   	   	  	  
